主要目的：本研究以福建海西新药创制股份有限公司的盐酸乐卡地平片（规格：10mg）为受试制剂，按生物等效性研究的有关规定，以原研厂家Recordati S.P.A.持有的盐酸乐卡地平片（规格：10 mg，商品名：再宁平®）为参比制剂，评估受试制剂和参比制剂在空腹条件下给药后的生物等效性。次要目的：观察受试制剂盐酸乐卡地平片和参比制剂盐酸乐卡地平片（再宁平®）在健康受试者中的安全性。

开始日期2025-09-02

申办/合作机构

福建海西新药创制股份有限公司

CTR20244642

/ CompletedN/A

盐酸乐卡地平片在健康受试者中单中心、随机、开放、两制剂、单次给药、四周期、完全重复交叉空腹生物等效性试验

主要目的：以药代动力学参数作为主要终点评价指标，比较在空腹状态下口服受试制剂盐酸乐卡地平片（规格：10mg，持证商：福建省宝诺医药研发有限公司）与参比制剂盐酸乐卡地平片（规格：10mg，持证商：Recordati S.P.A.，商品名：再宁平®）后在健康受试者体内的药代动力学行为，评价两种制剂的生物等效性。次要目的：观察空腹状态下受试制剂盐酸乐卡地平片和参比制剂盐酸乐卡地平片在健康受试者中的安全性。

开始日期2025-01-08

申办/合作机构

福建省宝诺医药研发有限公司

NCT07020104

/ RecruitingN/AIIT

The Role of Skin Sodium Accumulation in Chronic Kidney Disease

This project consists of four substudies: a cohort study (A) and a sodium intake intervention (B) and a sodium excretion intervention (C) and a water intervention study (D).
The main objective of the cohort study (A) is to investigate the prognostic implications of tissue sodium accumulation in CKD patients. The primary objective of the sodium intervention studies is to study the effect of high and low sodium intake (B) and increased renal sodium excretion (C) on tissue sodium content. The main objective of the water intervention study (D) is to investigate the effect of increased and habitual water intake on tissue sodium content and transepidermal water loss.

开始日期2025-01-07

申办/合作机构

Nierstichting Nederland

100 项与盐酸乐卡地平相关的临床结果

登录后查看更多信息

100 项与盐酸乐卡地平相关的转化医学

登录后查看更多信息

100 项与盐酸乐卡地平相关的专利（医药）

登录后查看更多信息

502

项与盐酸乐卡地平相关的文献（医药）

2026-05-01·TALANTA

Capillary blood microsampling and LC–Orbitrap analysis for adherence monitoring of cardiovascular drugs: method development, cross-validation, and patient proof-of-concept using VAMS and Capitainer-B

Article

作者: Meyer, Markus R ; Böhm, Michael ; Wagmann, Lea ; Mahfoud, Felix ; Markwirth, Philipp ; Kretschmer, Diana ; Tokcan, Mert

Microsampling enables decentralized adherence monitoring by capturing defined volumes of capillary blood. We developed, validated, and cross-evaluated a volumetric absorptive microsampling (VAMS) and Capitainer-B workflow for 15 cardiovascular drugs using high-resolution liquid chromatography Orbitrap analysis. Amlodipine, atenolol, atorvastatin, bisoprolol, carvedilol, clopidogrel, diltiazem, lercanidipine, metoprolol, nebivolol, prasugrel, rosuvastatin, salicylic acid, simvastatin hydroxy acid, and verapamil were included. Sampling by VAMS and Capitainer-B should be evaluated and compared. VAMS tips and Capitainer-B disks loaded with 10 μL whole blood were extracted with 200 μL methanol, shaken and centrifuged, evaporated to dryness, reconstituted, and injected for analysis. The method met international validation criteria for most analytes, with quantification and selectivity achieved for all except prasugrel. Capitainer-B generally exhibited higher matrix effects than VAMS, while accuracy and precision were within acceptance limits except for lercanidipine across both devices and for atorvastatin on Capitainer-B. Under long-term storage, VAMS showed >15 % loss for carvedilol, lercanidipine, and simvastatin hydroxy acid after two weeks, whereas Capitainer-B showed no degradation. In a proof-of-concept involving 30 patients, finger-prick concentrations from VAMS and Capitainer-B were interchangeable, supporting the suitability of these adherence workflows but reference ranges for capillary blood remain necessary to enable routine clinical interpretation. In summary, this work established a reliable, LC-Orbitrap-based microsampling platform for monitoring adherence and identified stability issued amongst others that guide future method selection and development.

2025-12-01·CELL BIOLOGY INTERNATIONAL

Cytogenotoxic Evaluation of Lercanidipine Hydrochloride in Human Lymphocytes Using Micronucleus, Chromosome Abnormalities, and Molecular Docking Assays

Article

作者: Kayraldiz, Ahmet ; Kenger, İbrahim Halil ; Yilmaz, Tuğçe Nur ; Kardöl, Ahmet ; Hüsunet, Mehmet Tahir

ABSTRACT:

This study evaluated the cytotoxic and genotoxic potential of lercanidipine hydrochloride (LHC) on human peripheral lymphocytes using in vitro and in silico approaches. The micronucleus (MN) test revealed a significant, dose‐dependent increase in MNs, particularly after 24‐h treatment (*** p < 0.001), which suggests potential DNA damage. However, the chromosome aberration (CA) test did not yield statistically significant results, although a dose‐related upward trend was observed. A substantial reduction in both the mitotic index (MI) and the nuclear division index (NDI) was observed at all concentrations (** p < 0.01, *** p < 0.001), indicating strong cytotoxic effects. In silico molecular docking analysis revealed that the ligand (LHC) binds to the minor groove of B‐DNA with a binding energy of −7.7 kcal/mol, forming non‐covalent interactions similar to those of the known minor groove binder Netropsin (−8.14 kcal/mol). By contrast, the positive control, mitomycin C (MMC), binds to the major groove via intercalation, forming covalent cross‐links, with a binding energy of −5.45 kcal/mol. Although LHC's minor groove binding suggests a potential preference for AT‐rich regions, its sequence specificity remains unconfirmed. Overall, these findings suggest that LHC primarily exhibits cytotoxic effects (e.g., inhibition of DNA replication or transcription), with only limited and preliminary evidence of genotoxic potential. Further studies are needed to elucidate the safety of LHC and its DNA interaction mechanisms.

2025-10-01·TALANTA

Voltammetric determination of lercanidipine in urine, blood plasma, and serum using hollow fiber-based liquid phase microextraction

Article

作者: Labzova, Oleksandra ; Šelešovská, Renáta ; Hrdlička, Vojtěch ; Navrátil, Tomáš

This study investigates a synergistic combination of hollow fiber-based liquid phase microextraction (HF-LPME) and voltammetric analysis using screen-printed boron-doped diamond electrodes (SP-BDDE) for the determination of antihypertensive drug lercanidipine (LCN) in urine, blood plasma, and blood serum. Optimum HF-LPME conditions were: dodecane as supported liquid membrane, Britton-Robinson buffer (BRB) pH 7 as donor solution, BRB pH 3 as acceptor solution, and extraction time 30 min. Square-wave voltammetry (SWV) of 10 μL acceptor solution at SP-BDDE was utilized with amplitude 75 mV, frequency 10 Hz, and potential step 4 mV. The calibration dependence of the combined HF-LPME-SWV method was established in the range of 1-1000 nmol L^-1, with limits of quantification (LOQ) and detection (LOD) of 3.3 and 1.1 nmol L^-1, respectively. The applicability of the developed method was verified by analysis of human urine, blood plasma, and blood serum samples spiked with 20 and 100 nmol L^-1 LCN with recoveries ranging from 93.2 to 112.9 % with respective RSDs 1.72-8.5 % (n = 3).

388

项与盐酸乐卡地平相关的新闻（医药）

2026-02-26

·知新行馆

心血管文献汇编 | IF >15 | 26.2.20-26.2.26

T细胞免疫治疗的心脏毒性期刊：Nat Rev CardiolPMID：41730987 简述：该综述总结了T细胞免疫治疗相关细胞因子释放综合征及后续心脏毒性的发生机制、流行病学特征与管理策略，探讨了对CAR-T细胞等新型T细胞治疗的深入认知如何指导心血管不良事件的预防与处理。摘要翻译: T细胞免疫治疗为肿瘤治疗提供了全新策略，嵌合抗原受体（CAR）T细胞治疗是其中应用最广泛的疗法，通过基因工程改造T细胞增强抗肿瘤效应。双特异性抗体、T细胞受体工程化T细胞及肿瘤浸润淋巴细胞也成为具有治疗价值的新型T细胞疗法。随着T细胞治疗种类及适用指征不断扩大，需要精准理解其潜在的血流动力学后遗症与心血管毒性。T细胞活化可引发大量细胞因子释放与过度炎症反应，即细胞因子释放综合征（CRS）。与其他炎症综合征类似，CRS可诱发心律失常、心肌梗死、心力衰竭等心血管并发症，重度CRS患者的心血管事件发生率高达20%。本综述总结了T细胞治疗相关CRS及后续心脏毒性的发生机制、流行病学特征与管理方案，同时探讨了对CAR-T细胞治疗及其他新兴T细胞疗法的深入认知，将如何为心血管不良事件的预防与管理提供依据。常规CT评估的主动脉与心脏结构可超越PREVENT评分及冠状动脉钙化评分预测心血管风险期刊：JACC Cardiovasc ImagingPMID：41718510 简述：本研究构建基于心脏和主动脉结构放射组学特征的预测模型，证实该模型预测主要不良心血管事件的效能优于PREVENT评分，且与冠状动脉钙化评分具有互补性，可识别传统临床评分漏诊的高危患者。摘要翻译: 背景：心血管疾病的预防依赖精准的风险评估，但现有评分系统精准度不足，常规影像学检查可被用于风险预测。目的：验证基于计算机断层扫描（CT）的心脏与主动脉结构特征，是否能在标准护理评分之外预测主要不良心血管事件（MACE）。方法：研究纳入美国国家肺癌筛查试验（NLST）中13437例肺癌筛查CT数据，提取心脏与主动脉结构的放射组学特征，通过最小绝对收缩和选择算子模型预测心血管死亡率；在麻省总医院布里格姆医疗体系中接受常规胸部CT且无既往主要不良心血管事件的患者中，将该评分与PREVENT评分、冠状动脉钙化（CAC）评分进行对比。采用Harrell C指数评估区分度，并计算PREVENT评分（风险≥7.5%）或放射组学评分（男性≥3.0%，女性≥1.5%）定义的高危人群的主要不良心血管事件发生率。结果：外部验证队列共14577例受试者，平均年龄61.1±8.6岁，男性占47.5%，中位随访5.7年期间6.2%发生新发主要不良心血管事件。放射组学评分对主要不良心血管事件的区分度优于PREVENT评分（C指数0.66，95%CI：0.64-0.68 vs 0.61，95%CI：0.59-0.63），且与冠状动脉钙化评分具有互补性（联合C指数0.69，95%CI：0.67-0.71 vs 单纯冠状动脉钙化评分0.66，95%CI：0.65-0.68）。仅放射组学评分判定为高危、而PREVENT评分未判定为高危的患者，其主要不良心血管事件发生率是双评分均为低危患者的3.6倍（每1000人年23.1例，95%CI：16.7-30.2 vs 6.5例，95%CI：5.5-7.5）。主动脉表面积体积比、左心室容积、左心房短轴长度是预测主要不良心血管事件的核心特征。结论：基于CT的心脏与主动脉结构放射组学可识别临床评分漏诊的高危患者，并在冠状动脉钙化评分风险分层基础上进一步细化风险，高危患者可从强化一级预防中获益。靶向高内皮微静脉的抗体药物偶联物促进心脏移植长期耐受期刊：CirculationPMID：41717681 简述：本研究揭示CHST4通过调控高内皮微静脉功能促进淋巴结内调节性T细胞生成、介导心脏移植耐受，研发的靶向高内皮微静脉的双载药抗体药物偶联物可显著延长小鼠心脏移植物存活并抑制慢性排斥反应。摘要翻译: 背景：初始T细胞进入淋巴结是共刺激阻断条件下诱导心脏移植耐受的关键步骤，淋巴结内特化血管即高内皮微静脉（HEVs）介导该过程。高内皮微静脉表达含6-磺基唾液酸化路易斯X的关键糖蛋白，该结构是初始T细胞膜上L-选择素的结合位点。该糖链的正常形成需要N-乙酰葡糖胺-6-O-磺基转移酶（尤其是CHST4）介导的磺基化修饰。鉴于CHST4在高内皮微静脉及移植免疫中的关键作用，本研究旨在研发一类靶向CHST4/高内皮微静脉轴的首创抗体药物偶联物（ADC），将免疫调节分子递送至淋巴结并促进心脏移植物长期存活。方法：采用CHST4敲除小鼠及可诱导白喉毒素受体小鼠模型，探究CHST4在心脏移植中对高内皮微静脉功能的作用；通过完全主要组织相容性复合体错配及单一Ⅱ类主要组织相容性复合体错配模型，分别研究CHST4缺失对心脏移植急性与慢性排斥反应的影响。构建靶向高内皮微静脉的双载药首创抗体药物偶联物，将雷帕霉素与土斯塔汀A偶联至MHA112抗体以诱导调节性T细胞，并在小鼠心脏移植模型中验证其疗效。结果：高内皮微静脉CHST4表达缺失会损伤初始T细胞向淋巴结的浸润，进而减少调节性T细胞生成，破坏共刺激阻断条件下的心脏移植耐受。搭载雷帕霉素与土斯塔汀A的靶向高内皮微静脉抗体药物偶联物治疗，可延长小鼠心脏移植物存活时间并抑制慢性排斥反应（移植物长期存活的主要障碍）。机制上，该抗体药物偶联物可增强淋巴结内调节性T细胞诱导、减少促炎T细胞并降低心脏移植物内免疫细胞浸润，且所需雷帕霉素与土斯塔汀A剂量远低于游离药物给药。结论：本研究揭示高内皮微静脉中CHST4在促进淋巴结内调节性T细胞生成、介导心脏移植耐受中的关键机制，同时提出基于CHST4的靶向高内皮微静脉抗体药物偶联物是抑制心脏移植排斥的潜在策略。射血分数保留型心力衰竭与代谢功能障碍相关脂肪性肝病：机制交汇与临床意义期刊：Nat Rev CardiolPMID：41735546 简述：该综述阐述射血分数保留型心力衰竭与代谢功能障碍相关脂肪性肝病的流行病学关联与共同代谢机制，解析肝脏-心脏间的双向器官对话，提出多器官整合的诊疗管理框架。摘要翻译: 射血分数保留型心力衰竭（HFpEF）与代谢功能障碍相关脂肪性肝病（MASLD）是全球肥胖与代谢综合征流行背景下发病率不断升高的相互关联疾病。二者曾被视为独立疾病，如今被认为是全身共同代谢功能障碍在不同器官的特异性表现。近十年证据显示二者不仅存在重叠危险因素，肝脏与心脏间还存在动态双向的器官对话，共同影响疾病自然病程。本综述探讨代谢功能障碍相关脂肪性肝病与射血分数保留型心力衰竭关联的流行病学与机制基础，聚焦脂毒性、代谢性炎症、氧化应激等共同代谢驱动因素；同时讨论影响心脏结构与功能的新兴肝脏介导因子，包括肝因子、代谢物及细胞外囊泡；最后梳理适用于两种疾病的诊疗策略，并提出多器官整合框架以优化临床识别与管理。理解肝-心轴是打破器官局限、以更整合的机制导向策略重新思考心血管代谢疾病的关键。 2050年美国女性心血管疾病与卒中疾病负担预测：美国心脏协会科学声明期刊：CirculationPMID：41738095 简述：本科学声明基于多项全国调查与人口普查数据，预测未来30年美国女性及女童心血管危险因素与疾病患病率将显著上升，少数族裔人群趋势更严峻，需全生命周期的临床与公共卫生干预。摘要翻译: 背景：预测心血管疾病与卒中的未来流行趋势，对指导改善女性全生命周期健康结局的工作至关重要。方法：基于2015-2020年美国国家健康与营养检查调查、2015-2019年医疗支出面板调查的历史趋势及人口增长普查估计，依据生命必备8项指标的不佳水平、临床心血管疾病与卒中的总体及年龄、种族、族裔分层数据，估算至2050年的流行趋势。结果：成年女性总体中，高血压患病率预计从2020年的48.6%升至2050年的59.1%；糖尿病（14.9%升至25.3%）、肥胖（43.9%升至61.2%）患病率上升，高胆固醇血症患病率下降（42.1%降至22.3%）。不良饮食、缺乏体力活动、吸烟患病率随时间下降，睡眠不足患病率上升。冠心病（6.85%升至8.21%）、心力衰竭（2.45%升至3.60%）、卒中（4.14%升至6.74%）、心房颤动（1.58%升至2.31%）及总心血管疾病与卒中（10.7%升至14.4%）患病率均上升。2-19岁女童呈现相似趋势，肥胖患病率预计从19.6%升至32.0%。美国印第安人/阿拉斯加原住民、多种族、黑人及西班牙裔女性与女童的不良趋势预计更为显著。结论：未来30年美国女性及女童心血管危险因素与疾病患病率将持续上升，需开展全生命周期的针对性临床与公共卫生干预以应对这些不良趋势。 CRISPR-Cas9碱基编辑敲除PKCα磷酸化可逆转心力衰竭期刊：Circ ResPMID：41717698 简述：本研究通过CRISPR-Cas9腺嘌呤碱基编辑技术敲除PKCα的T497磷酸化位点，在动物模型与人类诱导多能干细胞来源心肌细胞中证实该编辑可保护心脏功能、逆转心力衰竭，为心脏病治疗提供潜在基因编辑策略。摘要翻译: 背景：全球心力衰竭患病率持续升高且预后较差，亟需新型治疗策略。PRKCA基因编码的蛋白激酶Cα（PKCα）在心力衰竭发病机制中发挥核心作用，PKCα苏氨酸497位（T497）的磷酸化可触发一系列分子内磷酸化事件并使其激活，敲除T497磷酸化可降低PKCα的稳定性与活性。方法：通过CRISPR-Cas9介导的同源定向修复构建种系中携带PKCα抗磷酸化突变（T497A）的小鼠；为评估出生后基因组编辑的临床可行性，采用腺相关病毒9递送CRISPR-Cas9腺嘌呤碱基编辑器，在野生型小鼠中引入Prkca基因T497A突变（PrkcaT497A）。通过主动脉缩窄术构建心力衰竭小鼠模型，采用超声心动图、麦胚凝集素染色、Masson三色染色及RNA测序评估心脏功能、肥厚、纤维化及转录水平变化；通过Sanger测序与扩增子深度测序评估PrkcaT497A编辑效率。为进一步探究临床潜力，通过核转染介导的腺嘌呤碱基编辑在人类诱导多能干细胞中引入PRKCAT497A突变，在Fura-2负载的该突变细胞来源心肌细胞中分析慢性血管紧张素Ⅱ（AngII）刺激下的Ca²⁺稳态。结果：PKCα的T497A突变可阻止其后续磷酸化并引发PKCα蛋白降解。主动脉缩窄术后4周，野生型小鼠出现心脏功能受损、心脏重构及肺重量增加；与之相反，PKCα抗磷酸化小鼠可抵御心力衰竭相关的心肌肥厚、纤维化及心脏基因表达异常。接受腺相关病毒9递送碱基编辑器以抑制T497磷酸化的小鼠呈现相似的心脏保护作用。体外实验中，PKCα编辑的诱导多能干细胞来源心肌细胞可抵御血管紧张素Ⅱ诱导的收缩功能与Ca²⁺瞬态损伤。结论：通过腺嘌呤碱基编辑实现PRKCAT497A编辑是人类心脏疾病的潜在治疗手段。急性心脏病住院患者的营养不良与恶病质：美国心脏协会科学声明期刊：CirculationPMID：41732869 简述：本科学声明指出急性心血管疾病住院患者营养不良患病率达20%-60%，营养不良与不良预后相关，推荐住院48小时内启动肠内营养，明确肠内与肠外营养的适用场景。摘要翻译: 营养不良可累及各类急性心血管疾病患者，包括急性冠状动脉综合征、心律失常、瓣膜病患者，但现有文献多聚焦心力衰竭患者。住院患者的营养不良患病率估计为20%至60%。采用全球营养不良领导倡议标准诊断心血管疾病患者营养不良，证实其具有预后价值，与躯体功能下降及死亡率升高相关。营养支持在住院患者（尤其是心脏重症监护室患者）中发挥关键作用，包括住院48小时内启动喂养，优先选择肠内营养。肠内营养较肠外营养更具成本效益，可降低死亡率并缩短住院时长。肠外营养仅适用于严重胃肠道功能障碍患者，或肠内营养禁忌时（如大剂量升压药导致肠道灌注不足、首周营养摄入目标未达70%时）的营养补充。心源性休克患者的最佳蛋白质摄入量仍在研究中，近期重症监护试验显示高蛋白摄入方案无明显获益。血小板工程化RNA疗法时空重编程心脏脂质代谢可表观遗传调控心脏修复与再生期刊：Bioact MaterPMID：41716677 简述：本研究构建血小板包裹介孔二氧化硅纳米颗粒载CD36靶向siRNA的生物响应递送系统，可靶向心肌损伤部位重编程心肌细胞脂质代谢、表观遗传修饰，促进心肌细胞增殖且无脂毒性，为缺血性心脏病再生基因治疗提供平台。摘要翻译: 缺血性心脏病仍是全球主要的发病与死亡原因，其核心诱因是心肌细胞不可逆丢失及再生能力受限。抑制脂肪酸氧化（FAO）具有恢复心肌细胞增殖的潜力，但全身性抑制线粒体脂肪酸氧化通常会导致脂质蓄积与代谢应激。通过关键跨膜转运蛋白CD36靶向调控脂肪酸摄取，是在最小化脂毒性的同时选择性抑制脂肪酸氧化的更优策略。本研究报道一种生物响应性siRNA递送系统，由血小板包裹介孔二氧化硅纳米颗粒（Plt-MSNs）负载CD36靶向siRNA构成。利用血小板的开放小管系统，血小板可内化siRNA载药，并通过自身归巢特性将其特异性递送至心肌损伤部位。在小鼠缺血再灌注模型中，血小板包裹介孔二氧化硅纳米颗粒实现了CD36靶向siRNA的靶向递送与刺激响应释放，有效重编程心肌细胞脂质代谢、重塑表观遗传图谱，最终促进心肌细胞增殖且无脂质毒性。该方法通过代谢-表观遗传重编程为再生基因治疗提供了全新平台。心血管科学、医学与社会：全新世界——2025年美国心脏病学会布劳恩瓦尔德讲座期刊：J Am Coll CardiolPMID：41739019 简述：该综述回顾心血管医学领域的里程碑进展，包括新型治疗药物、基因与RNA疗法、微创介入技术、人工智能与数字健康，同时探讨医疗公平、伦理等挑战，提出将科研成果转化为公平负责任医疗的展望。摘要翻译: 近期科技进步极大拓展了心血管医学的发展空间，里程碑式临床试验为脂质紊乱、心力衰竭、肥胖带来变革性治疗方案，为临床医师管理复杂患者群体提供了全新有力工具。分子医学领域的基因治疗、RNA治疗等发现催生了新型生物制药平台，有望实现治愈性或低频给药方案。微创经皮与机器人外科技术、新一代器械及介入操作提升了患者结局并扩大了高级医疗可及性。人工智能与数字健康技术的快速崛起，重塑了医疗全流程中数据的采集、解读与应用方式。这些进展共同标志着心血管医学进入全新时代，但该时代的潜力受限于医疗可及性不均、伦理困境及患者与社会层面的潜在非预期后果。本综述为致敬心血管科学与技术创新先驱尤金·布劳恩瓦尔德博士而撰写，总结了心血管医学近期里程碑事件，并前瞻性探讨如何通过将科研进展转化为公平、负责任的医疗服务与更佳健康结局，充分实现创新价值。非急性心肌缺血综合征的有创治疗与药物治疗策略期刊：Nat Rev CardiolPMID：41714707 简述：本文为综述，回顾近二十年冠心病管理领域经皮冠状动脉介入、冠脉旁路移植术、药物二级预防等关键进展，聚焦非急性心肌缺血综合征的临床决策，基于现代最佳药物治疗时代的高质量随机对照试验，分析有创联合最佳药物治疗对比单纯保守治疗的风险获益，明确不同风险患者的一线治疗与进阶干预策略，并提出规范化管理路径。摘要翻译：过去二十年间，随着经皮冠状动脉介入治疗（PCI）、冠状动脉旁路移植术（CABG）、药物二级预防、抗心绞痛药物及生活方式干预的进步，冠心病患者的管理策略已得到显著改善。因此，非急性心肌缺血综合征（NAMIS）的临床管理选择仍是一个适时且重要的课题。临床应与患者探讨有创策略联合最佳药物治疗（OMT）对比单纯OMT保守策略的风险与获益，以推动临床共同决策。现代OMT时代的高质量随机对照试验结果为上述知情沟通提供了重要基础。总体而言，随机对照试验证据支持将OMT作为NAMIS患者的一线治疗方案，而部分解剖高危患者或初始OMT治疗后仍存在持续性心绞痛症状的患者，往往可通过PCI有创治疗进一步缓解症状。在包括多支血管病变及糖尿病在内的高危NAMIS患者中，CABG手术可改善患者生存率，而PCI的获益尚不明确。本综述探讨了近期评估NAMIS患者接受有创治疗或单纯OMT保守治疗预后的临床试验结果，并最终提出了推荐的管理路径。 Pelacarsen与脂蛋白(a)分离术在心血管病二级预防中的应用：Lp(a)FRONTIERS APHERESIS试验期刊：Eur Heart JPMID：41721795 简述：本项随机对照试验针对高脂蛋白(a)合并确诊心血管病患者，探究Pelacarsen对脂蛋白分离术需求的影响，结果证实Pelacarsen可大幅降低分离术频次、显著提升患者脱离该治疗的概率，且安全性与耐受性良好。摘要翻译：背景与目的：脂蛋白分离术（LA）是目前唯一获批用于高脂蛋白(a)［Lp(a)］患者的治疗手段。Lp(a)FRONTIERS APHERESIS试验探究了Pelacarsen能否降低高Lp(a)且确诊心血管疾病（CVD）德国患者对LA的治疗需求。方法：将既往1年接受≥35次LA治疗、Lp(a)水平＞60 mg/dl的成年患者随机分组，分别接受Pelacarsen 80 mg或安慰剂每4周一次治疗，持续52周；若前次随访Lp(a)＞60 mg/dL，则每周行LA治疗。主要终点为实际LA治疗频次相对于每周计划LA方案的标准化比率（52周内实际LA次数/计划LA次数）。次要终点为连续≥24周脱离LA治疗的时间，以及第12周至第52周的总体LA治疗脱离情况。结果：共51例患者被随机分组（平均年龄61.7岁，基线平均Lp(a)85.4 mg/dL，既往12个月平均LA治疗44.0次），Pelacarsen组26例中有25例（96.2%）、安慰剂组25例中有23例（92.0%）完成研究，两组基线特征基本均衡。Pelacarsen显著降低LA平均治疗比率（0.16对比安慰剂0.93，比值比0.006，95%置信区间［CI］0.003~0.013；P＜.0001），大幅提升实现脱离LA治疗的风险比（风险比：88.3；P＝.0014；实现脱离治疗中位时间：6.1周）及总体LA治疗脱离率（比值比：163.2；P＝.0005）。第52周时，Pelacarsen较安慰剂使Lp(a)相对基线下降72%（95%CI：-79%~-61%；P＜.0001）。两组治疗相关不良事件发生率相近，仅注射部位红斑多为轻度（Pelacarsen组38.5%；安慰剂组0%）。结论：Pelacarsen是一种高效且耐受性良好的靶向Lp(a)治疗药物，可显著降低高Lp(a)合并确诊CVD患者对LA治疗的需求。急性肺栓塞的机械取栓术与导管介导溶栓术：PERT联盟注册研究（2016-2024）的应用趋势与临床实践模式期刊：J Am Coll CardiolPMID：41739022 简述：本研究基于美国PERT联盟前瞻性注册数据，分析2016-2024年中高危急性肺栓塞患者导管介入治疗的应用趋势，发现机械取栓术逐年快速增长并取代导管介导溶栓术成为主流，且治疗向更高危患者倾斜，提示需随机对照研究明确最优患者选择标准。摘要翻译：背景：尽管缺乏证实临床获益的高质量随机数据，过去十年间导管介入治疗已彻底改变急性肺栓塞（PE）的治疗格局。此外，描述其真实世界普及情况、患者选择及预后的多中心数据仍较为有限。目的：本研究旨在分析2016-2024年肺栓塞救治团队（PERT）联盟注册研究中，导管介导溶栓术（CDT）与机械取栓术（MT）的全国应用趋势、患者及影像学特征，以及不同医疗中心的应用差异。方法：研究者分析了来自美国48家中心、前瞻性PERT注册研究中2958例接受进阶治疗的中高危PE患者数据。采用混合效应泊松模型评估全身溶栓、CDT及MT的应用时间趋势；通过带中心水平随机截距的混合效应逻辑回归分析MT与CDT应用的相关因素。按欧洲心脏病学会2019年风险分层对患者进行分组，采用复合肺栓塞评分（CPES）进一步评估患者病情危重程度。结果：2958例接受进阶治疗的患者中，75.9%为中危PE，24.1%为高危PE。MT应用率每年增长18%（事件发生率比［IRR］：1.18；95%CI：1.14~1.23），2021年起超过CDT；而CDT与全身溶栓应用率分别每年下降13%和12%。MT与年龄≥70岁（比值比OR：1.37；95%CI：1.04~1.81）、男性（OR：1.54；95%CI：1.19~1.99）、血管加压药使用、体外膜肺氧合支持、骑跨型栓塞或移行性血栓独立相关；CDT则更多用于年轻女性患者及存在心肺症状的患者。研究期间，接受治疗的高危患者比例及平均CPES评分均升高，提示导管介入治疗逐步应用于病情更危重的患者。结论：过去十年间，MT迅速取代CDT成为急性PE的主要导管介入治疗方式，反映了技术革新与术者信心的提升。PERT注册研究记录了这一技术革新在不同中心及患者群体中的普及过程，显示治疗向病情更重的患者倾斜，且多学科操作整合程度提升。这些结果强调，亟需随机对照研究明确不同器械类别下的最优患者选择标准及对比预后。 PGK1通过调控波形蛋白/PI3K/Akt通路介导心肌肥厚期刊：Circ ResPMID：41732856 简述：本基础研究证实磷酸甘油酸激酶1（PGK1）在病理性心肌肥厚中表达上调并发挥关键作用，其可作为蛋白激酶磷酸化波形蛋白，激活下游PI3K/Akt通路并促进心肌细胞铁死亡，靶向抑制PGK1可缓解心肌肥厚，为治疗提供新靶点。摘要翻译：背景：病理性心肌肥厚是心力衰竭的主要危险因素。磷酸甘油酸激酶1（PGK1）在细胞能量代谢中发挥重要作用，但其在心肌肥厚中的功能尚未明确。方法：检测心肌肥厚患者及主动脉缩窄或血管紧张素Ⅱ（Ang Ⅱ）处理小鼠心肌组织中PGK1的表达、活性及其代谢产物3-磷酸甘油酸水平；采用液相色谱-串联质谱及免疫共沉淀分析鉴定PGK1的互作蛋白；在小鼠心肌肥厚模型中评估PGK1抑制剂CBR-470-1的潜在作用。结果：在心肌肥厚小鼠及患者的心肌组织中均观察到PGK1激活与表达上调。心肌细胞特异性PGK1敲除可缓解小鼠心肌肥厚及心功能异常；相反，心肌细胞特异性PGK1过表达或输注3-磷酸甘油酸可加重心肌肥厚。机制上，PGK1作为蛋白激酶促进波形蛋白（Ser83）磷酸化，进而通过FAK/Src介导PI3K/Akt磷酸化；激活的波形蛋白/PI3K/Akt信号通路可促进心肌细胞铁死亡。CBR-470-1抑制PGK1可在细胞及动物模型中预防心肌肥厚。结论：本研究证实PGK1在心肌肥厚中发挥关键作用，其通过下游激活波形蛋白/PI3K/Akt/铁死亡通路介导疾病进展。 TMC6是病理性心肌肥厚的新型治疗靶点期刊：Circ ResPMID：41738082 简述：本研究发现跨膜通道样蛋白6（TMC6）在肥厚心肌中表达下调，其可通过内质网锚定结合CIB1蛋白，抑制钙调磷酸酶/NFAT通路从而抑制病理性心肌肥厚，恢复TMC6表达可逆转压力负荷诱导的心肌重构，提示TMC6-CIB1轴为潜在治疗靶点。摘要翻译：背景：机械应激驱动的病理性心肌肥厚是心力衰竭的主要病因，目前有效的治疗靶点仍有限。跨膜通道样蛋白6（TMC6）在健康心肌中高表达，在肥厚心肌中表达下调，其在心肌肥厚中的作用尚不明确。方法：结合主动脉缩窄术后心脏特异性Tmc6敲除小鼠、新生大鼠心室肌细胞及CRISPR/Cas9编辑的人多能干细胞衍生心肌细胞，评估心肌肥厚及信号通路变化；通过亚细胞定位、蛋白互作及竞争性多肽实验解析分子机制；采用9型腺相关病毒（AAV9）-cTnT-TMC6进行体内功能挽救实验。结果：体内外实验显示，TMC6缺失可增大心肌细胞体积、升高胎儿基因表达并诱发不良重构；而TMC6过表达可抑制肥厚反应。全长TMC6定位于内质网，与钙整合素结合蛋白1（CIB1）结合并将其锚定在内质网，限制CIB1进入肌膜Ca²⁺微区，而该区域是支架钙调磷酸酶并激活活化T细胞核因子（NFAT）的关键位点。可穿透细胞的TMC6₁₆₁₋₁₈₀多肽可竞争性将CIB1从TMC6上解离，加重野生型而非Tmc6敲除心肌细胞的肥厚反应，提示其显性负性调控机制。治疗层面，AAV9-cTnT-TMC6可恢复TMC6-CIB1结合，抑制钙调磷酸酶/NFAT通路活化，改善压力负荷后的心脏功能。结论：TMC6是病理性心肌肥厚的内源性抑制因子，其通过内质网锚定CIB1抑制CIB1-钙调磷酸酶/NFAT信号通路。恢复全长TMC6可缓解压力负荷诱导的心肌重构，提示TMC6-CIB1轴可作为治疗靶点。心肌损伤中cTnI/cTnT比值的临床价值：多队列研究与实验验证期刊：J Am Coll CardiolPMID：41739020 简述：本大样本多队列研究挑战了临床中cTnI与cTnT可互换使用的观点，证实cTnI/cTnT比值可区分急性坏死性与慢性/非坏死性心肌损伤，并提升1型与2型急性心肌梗死的鉴别效能，具有重要诊断价值。摘要翻译：背景：尽管初步研究提示心肌肌钙蛋白I（cTnI）/cTnT比值在急性坏死性与慢性或非坏死性心肌损伤中存在差异，但临床实践中仍将二者互换使用。目的：本研究旨在挑战cTnI与cTnT的互换性，在大样本经判定的多队列人群中验证cTnI/cTnT比值作为心肌损伤类型及严重程度生物学标志物的价值，在不同检测方法及外部数据集中验证信号可靠性，并结合实验模型复现该信号趋势。方法：将3项前瞻性临床研究中经中心判定诊断的受试者分为无已知心脏病、慢性心脏病及急性心脏病组；检测血浆高敏cTnI（Architect）及高敏cTnT（Elecsys）浓度，通过回归模型分析cTnI/cTnT比值与诊断分类的关联及诊断效能。完成内部及外部验证，并在4种模拟轻度非致死性及致死性损伤的心肌细胞实验模型中进一步探究该比值。结果：9704例受试者中，急性心脏病组cTnI/cTnT比值最高（2.06；95%CI：1.89~2.26），约为慢性心脏病组（0.66；95%CI：0.60~0.72）及无已知心脏病组（0.50；95%CI：0.43~0.59）的4倍。该结果在不同高敏cTnI检测方法及外部验证队列中保持一致。实验模型中，轻度非致死性损伤以cTnT释放为主（cTnI/cTnT比值约0.5），致死性损伤以cTnI释放为主（cTnI/cTnT比值＞1）。在包含cTnI、cTnT的统计模型中加入cTnI/cTnT比值作为预测因子，可提升1型与2型急性心肌梗死的鉴别效能（曲线下面积AUC 0.73；95%CI：0.70~0.76 vs 0.70；95%CI：0.67~0.73；P＜0.01）。结论：临床及实验研究证实，cTnI/cTnT比值可区分急性坏死性与慢性/非坏死性心肌损伤，并提升1型与2型急性心肌梗死的鉴别能力，具有潜在诊断价值，同时挑战了cTnI与cTnT可互换使用的观点。三维超声心动图在瓣膜性心脏病中的应用：临床意义期刊：Eur Heart JPMID：41721505 简述：本文为综述，阐述三维超声心动图在经胸及经食管瓣膜性心脏病评估中的精准可视化优势，强调其在经导管瓣膜介入治疗规划、术中引导中的核心作用，总结技术进展与临床应用价值。摘要翻译：三维（3D）超声心动图已成为瓣膜性心脏病（VHD）评估与管理的重要工具，经胸及经食管途径应用时均具备更高的诊断准确性及更精细的可视化效果。经导管瓣膜介入治疗的兴起（尤其适用于高危或无法手术患者）凸显了3D成像在术中引导中的重要性。三维超声心动图可精准评估瓣膜解剖结构、量化反流程度并可视化复杂病变，助力优化手术规划及改善预后。这些技术进步提升了经导管介入治疗的引导精度，改善了手术整体安全性及成功率。本综述强调三维超声心动图在瓣膜性心脏病管理中日益重要的作用，重点阐述其技术发展及在精准诊断、手术引导中的应用。射血分数降低、轻度降低及保留的心力衰竭预后：ESC HF Ⅲ注册研究期刊：Eur Heart JPMID：41736503 简述：本项欧洲多中心注册研究纳入超1万例心力衰竭患者，分析不同射血分数分型心衰的院内及1年预后，证实急性心衰院内死亡率为5.1%且与射血分数降低相关，急性心衰患者1年事件率显著高于门诊心衰患者，为欧洲心衰管理提供真实世界数据。摘要翻译：背景与目的：评估当代欧洲心脏病学会（ESC）心力衰竭（HF）Ⅲ注册研究中，不同类型心衰患者的院内及1年病因特异性预后。方法：在欧洲及ESC附属国家纳入心衰患者，详细记录临床特征及病因特异性预后数据。结果：2018年11月1日至2020年12月31日，41个国家220个中心共纳入10162例患者，其中39%为急性心衰（AHF，年龄70［62~79］岁，36%为女性），61%为门诊心衰患者（年龄66［58~75］岁，33%为女性）。总体而言，58%为射血分数降低心衰（HFrEF），17%为射血分数轻度降低心衰（HFmrEF），25%为射血分数保留心衰（HFpEF）。急性心衰患者中位住院时长9（6~14）天，院内死亡率5.1%（HFrEF 5.2%；HFmrEF 4.8%，HFpEF 3.4%）。对存活出院的急性心衰患者及门诊心衰患者进行中位376（360~432）天随访，每100患者年的全因、心血管（CV）及不明原因死亡率分别为：急性心衰HFrEF组19、13、3.0；急性心衰HFmrEF组22、11、6.3；急性心衰HFpEF组16、7.0、4.7；门诊HFrEF组6.6、4.3、0.9；门诊HFmrEF组4.0、2.6、0.8；门诊HFpEF组3.9、1.7、1.2。至少1次心衰再住院率分别为：急性心衰HFrEF组44%、急性心衰HFmrEF组42%、急性心衰HFpEF组36%、门诊HFrEF组21%、门诊HFmrEF组14%、门诊HFpEF组18%。结论：欧洲及附属国家心衰患者院内死亡率为5.1%，射血分数越低死亡率越高。出院存活者及门诊患者1年随访中，每100患者年死亡率3.9~22、心血管死亡率1.7~13、不明原因死亡率0.8~6.3；1年内心衰再住院率14%~44%，急性心衰后再住院率约为门诊心衰患者的2倍。心源性猝死相关疾病的心脏筛查：104369例年轻个体的检出率、干预措施及心搏骤停/心源性猝死发生率期刊：J Am Coll CardiolPMID：41738673 简述：本大样本回顾性研究评估普通年轻人群心源性猝死相关疾病的单次心脏筛查价值，筛查检出0.3%的高危个体且41%接受风险修正干预，长期随访仍有少量新发病例，提示单次筛查存在局限，需强化连续评估策略。摘要翻译：背景：心源性猝死（SCD）的预防措施（含心脏筛查）多聚焦于年轻运动员，普通年轻人群心源性猝死相关疾病筛查的影响数据仍有限。目的：明确年轻个体单次心脏筛查对心源性猝死相关疾病的诊断检出率、初次筛查合格后的后续心脏诊断情况，以及心搏骤停（SCA）及SCD的发生率。方法：2008-2018年，104369例连续14~35岁受试者（62%为男性，89%为白种人，9%为运动员）接受单次筛查，包括问卷、心电图（ECG）及选择性超声心动图，所有受试者均由心内科主治医师解读结果并酌情建议二次心脏评估。通过国家数据库及随访问卷获取预后数据。结果：104369例筛查者中，2619例（2.5%）被转诊行二次评估，其中937例（0.9%）因症状或家族史高危、1361例（1.3%）因心电图异常、321例（0.3%）因二者兼有。筛查共确诊280例（0.3%）心搏骤停/心源性猝死相关疾病患者，其中115例（41%）接受风险修正干预，包括10例预防性植入式心律转复除颤器及2例心脏移植。平均随访6.0±2.5年，另有86例（0.08%）确诊心搏骤停/心源性猝死相关疾病，其中35例发生心搏骤停（n=15）或心源性猝死（n=20）。心搏骤停/心源性猝死发生率为5.6/10万人年，发病中位年龄23.8岁（四分位距IQR：10.5），事件发生于筛查后中位3.6年（范围：0.2~11.7）。心电图及问卷检测心搏骤停/心源性猝死相关疾病的灵敏度分别为75.4%、32.5%。结论：单次心脏筛查在0.3%的年轻个体中检出心搏骤停/心源性猝死相关疾病，其中41%接受生活方式及药物之外的风险修正干预。6年随访中，0.08%筛查合格个体后续确诊相关疾病或发生心搏骤停/心源性猝死，心搏骤停/心源性猝死发生率为5.6/10万人年，提示需强化年轻人群心源性猝死预防策略，连续评估可缓解年龄相关外显率带来的挑战。房颤患者联用阿哌沙班/利伐沙班与地尔硫卓对比美托洛尔的出血风险期刊：Ann Intern MedPMID：41730211 简述：本回顾性队列研究发现，房颤患者服用Xa因子抑制剂（阿哌沙班/利伐沙班）时，联用高剂量地尔硫卓较低剂量地尔硫卓或美托洛尔，严重出血风险显著升高，为临床联合用药安全提供依据。摘要翻译：背景：地尔硫卓是细胞色素P450 3A4及P-糖蛋白底物的强效抑制剂，可影响Xa因子抑制剂的代谢途径，增加房颤（AF）患者严重出血并发症风险。目的：对比房颤患者联用阿哌沙班或利伐沙班与地尔硫卓，对比联用美托洛尔的出血风险。设计：回顾性队列活性对照研究。场所：美国行政医疗保健数据库。患者：房颤患者。干预：房颤患者使用阿哌沙班或利伐沙班联合地尔硫卓或美托洛尔。检测指标：主要终点为导致住院的严重出血事件复合终点；次要终点为卒中或全身性栓塞复合终点。地尔硫卓分为高剂量（＞120 mg/d）及低剂量（≤120 mg/d），采用倾向得分匹配校正地尔硫卓与美托洛尔使用者的组间差异。结果：匹配后的房颤队列中，地尔硫卓组与美托洛尔组各23000例。倾向得分匹配后，地尔硫卓（对比美托洛尔）与更高的出血事件风险相关（率差RD：5.4/1000人年，95%CI：1.2~9.6）。高剂量地尔硫卓出血风险高于低剂量（高剂量RD：9.2，CI：2.7~15.7；低剂量RD：2.6，CI：0.5~8.0）。地尔硫卓与美托洛尔的12个月及6个月风险差估计值分别为0.48个百分点（CI：0.09~0.83）、0.31个百分点（CI：0.04~0.58）。局限性：存在残余混杂因素。结论：接受阿哌沙班或利伐沙班治疗的商业保险房颤患者中，联用较美托洛尔，地尔硫卓与严重出血并发症风险升高相关。 2型糖尿病患者使用GLP-1受体激动剂对比DPP-4抑制剂或SGLT-2抑制剂的心力衰竭住院风险：一项目标试验模拟研究期刊：CirculationPMID：41732861 简述：本研究依托瑞典斯德哥尔摩人群医疗数据模拟两项目标试验，对比2型糖尿病患者初始使用GLP-1受体激动剂、DPP-4抑制剂与SGLT-2抑制剂的心力衰竭住院风险，结果显示GLP-1受体激动剂较DPP-4抑制剂可降低心力衰竭住院风险，与SGLT-2抑制剂风险水平相近。摘要翻译: 背景：2型糖尿病患者无论是否有心力衰竭病史，均亟需新型方案进行心力衰竭的一级与二级预防。目前关于胰高血糖素样肽-1受体激动剂（GLP-1RAs）能否降低该广泛人群的心力衰竭住院风险，以及该作用是类效应还是因具体药物而异，临床试验证据存在矛盾。此外，其与钠-葡萄糖协同转运蛋白2抑制剂（SGLT-2is）的对比疗效尚不明确。方法：本研究利用瑞典斯德哥尔摩2010-2021年的人群医疗数据模拟2项目标试验。目标试验1纳入初始使用GLP-1RA对比二肽基肽酶4抑制剂（DPP-4is）的2型糖尿病成年患者，目标试验2对比GLP-1RA与SGLT-2i。主要结局为心力衰竭住院。采用Cox回归估算意向治疗风险比，通过治疗逆概率加权平衡72个混杂因素。主要不良心血管事件作为阳性对照结局。研究对GLP-1RA整体类别及利拉鲁肽、司美格鲁肽等单个药物分别进行分析。结果：目标试验1纳入32979例患者（42%使用GLP-1RA，58%使用DPP-4i），平均年龄64岁，女性占40%；目标试验2纳入30104例患者（49%使用GLP-1RA，51%使用SGLT-2i），平均年龄63岁，女性占38%。与起始DPP-4i相比，起始GLP-1RA治疗的患者3年心力衰竭住院绝对风险更低（3.4% versus 4.3%），加权风险比为0.77（95% CI，0.66-0.91）。GLP-1RA与SGLT-2i对比的3年心力衰竭住院绝对风险分别为3.6%和3.3%，加权风险比为1.02（95% CI，0.85-1.18）。基线心力衰竭预测风险较高的患者，绝对风险差异最为显著。单个药物分析、符合方案分析及多数亚组结果均保持一致。阳性对照结局分析显示，GLP-1RA较DPP-4i可降低主要不良心血管事件发生率（加权风险比0.85[95% CI，0.74-0.99]），与临床试验结果相符。结论：在2型糖尿病常规临床诊疗中，与DPP-4i相比，使用GLP-1RA可降低心力衰竭住院风险；与SGLT-2i相比，二者心力衰竭住院风险相近。阿司匹林使用、脂蛋白(a)与钙化性主动脉瓣疾病：多种族动脉粥样硬化研究期刊：Eur Heart JPMID：41721439 简述：本项观察性研究探索阿司匹林使用与不同脂蛋白(a)、低密度脂蛋白胆固醇水平人群新发主动脉瓣钙化及重度主动脉瓣狭窄的关联，发现规律服用阿司匹林可降低高脂蛋白(a)人群的上述疾病发病风险，对高低密度脂蛋白胆固醇人群无此保护作用。摘要翻译: 背景与目的：脂蛋白(a)[Lp(a)]与低密度脂蛋白胆固醇（LDL-C）与主动脉瓣钙化（AVC）及主动脉瓣狭窄（AS）存在因果关联。脂蛋白(a)具有抗纤溶特性，因此阿司匹林或可降低高脂蛋白(a)人群的心血管疾病风险。本分析旨在明确不同脂蛋白(a)与低密度脂蛋白胆固醇水平下，阿司匹林使用与新发主动脉瓣钙化、主动脉瓣狭窄的关联。方法：本观察性研究纳入多种族动脉粥样硬化研究中至多6598名受试者。通过非对比心脏计算机断层扫描检测主动脉瓣钙化。采用多变量Cox风险回归分析，按脂蛋白(a)与低密度脂蛋白胆固醇分层，评估自我报告规律服用阿司匹林（每周≥3天）与新发主动脉瓣钙化、重度主动脉瓣狭窄的关联。受试者未被告知主动脉瓣钙化与脂蛋白(a)检测结果。结果：受试者平均年龄62岁，女性占53%，23%规律服用阿司匹林，8%发生主动脉瓣钙化（中位随访8.9年），1%发生重度主动脉瓣狭窄（中位随访16.7年）。在脂蛋白(a)升高人群中，规律服用阿司匹林与更低的新发主动脉瓣钙化风险相关[脂蛋白(a)≥75 mg/dL：风险比0.42，95%置信区间0.19-0.93；脂蛋白(a)≥100 mg/dL：风险比0.17，95%置信区间0.04-0.67]，也与更低的重度主动脉瓣狭窄风险相关[脂蛋白(a)≥50 mg/dL：风险比0.13，95%置信区间0.04-0.47；脂蛋白(a)≥75 mg/dL：风险比0.02，95%置信区间0.001-0.29]。在低密度脂蛋白胆固醇升高人群中，规律服用阿司匹林与新发主动脉瓣钙化[低密度脂蛋白胆固醇≥130 mg/dL：风险比1.02，95%置信区间0.66-1.58；低密度脂蛋白胆固醇≥160 mg/dL：风险比1.51，95%置信区间0.53-4.28]及重度主动脉瓣狭窄[低密度脂蛋白胆固醇≥100 mg/dL：风险比0.70，95%置信区间0.39-1.26；低密度脂蛋白胆固醇≥130 mg/dL：风险比0.46，95%置信区间0.14-1.47]均无关联。结论：在这项前瞻性观察队列数据的探索性分析中，规律服用阿司匹林与高脂蛋白(a)人群主动脉瓣钙化及重度主动脉瓣狭窄风险降低相关，与高低密度脂蛋白胆固醇人群无此关联。需开展验证性研究明确阿司匹林在高脂蛋白(a)人群主动脉瓣钙化与主动脉瓣狭窄预防中的作用。响应活性氧的水凝胶贴片调控巨噬细胞重编程与线粒体保护用于心肌梗死后修复期刊：Bioact MaterPMID：41727273 简述：本研究针对心肌梗死引发的心肌细胞不可逆丢失、氧化应激、炎症及纤维化重构问题，通过网络药理学筛选出丹酚酸B为心梗治疗候选药物，进而开发负载丹酚酸B的可注射活性氧响应型水凝胶贴片，实现局部按需释药，在小鼠心梗模型中减轻纤维化、促进血管生成并恢复心功能。摘要翻译: 心肌梗死会导致心肌细胞不可逆丢失，同时伴随氧化应激、炎症反应与纤维化重构，最终进展为心力衰竭。通过网络药理学分析，丹参主要活性成分丹酚酸B被筛选为心梗治疗的潜在候选药物。丹酚酸B口服给药在心脏功能、分子及组织学评估中均展现出治疗效果，但其生物利用度差限制了临床转化。为克服该局限，本研究开发了一种可注射的活性氧（ROS）响应型水凝胶贴片用于心梗局部修复。该水凝胶由甲基丙烯酸化乳清分离蛋白与邻硝基苄醇修饰的透明质酸构成，通过动态共价键形成生物相容且具有黏附性的网络结构。研究将包载丹酚酸B的活性氧敏感脂质体整合入水凝胶，使其可响应梗死区氧化微环境实现局部按需释药。体外研究证实该水凝胶具备良好的机械强度、特异性心肌黏附性与持续抗氧化能力。在小鼠心梗模型中，单次给予该水凝胶贴片可显著减轻纤维化、促进血管生成并恢复心脏功能。本研究建立了一套合理的设计策略：从基于网络药理学的药物筛选，到治疗效果验证，最终构建响应型递送系统，为心梗后局部持续心脏修复提供了极具前景的方案。 FOXO1整合动脉粥样硬化中内皮细胞的血流动力学、炎症与代谢通路期刊：Circ ResPMID：41738126 简述：本研究揭示转录因子FOXO1是连接紊乱血流、内皮炎症与动脉粥样硬化的关键分子，紊乱血流与炎症因子可诱导其核转位促进动脉粥样硬化，生理性层流则通过KLF2-CDK2通路抑制其入核，为动脉粥样硬化性心血管疾病提供新治疗靶点。摘要翻译: 背景：动脉粥样硬化好发于流体剪切应力紊乱区域，而生理性层流剪切应力可通过抑制内皮炎症发挥保护作用。促炎症与抗炎程序分别与糖酵解、氧化磷酸化相关，但具体机制尚不明确。转录因子FOXO1可调控内皮代谢与血管生成，但其在内皮炎症中的作用鲜有报道。方法：体外采用平行板流动腔对内皮细胞给予细胞因子处理或特定流体剪切应力刺激，通过免疫荧光、RNA测序与生化实验检测FOXO1定位、基因表达及翻译后修饰。体内实验将FOXO1条件敲除小鼠与Bmx-CreERT2小鼠杂交，实现动脉内皮细胞特异性FOXO1敲除。通过注射PCSK9腺相关病毒联合高胆固醇高脂饮食诱导高脂血症，评估动脉粥样硬化病变。结果：振荡剪切应力与炎症因子可诱导FOXO1核转位，而生理性剪切应力可抑制该过程。内皮细胞敲除FOXO1可上调保护性血流响应转录因子KLF2/4，并降低振荡剪切应力诱导的炎症基因表达。生理性剪切应力通过KLF2-CDK2通路抑制FOXO1核转位，其中CDK2可使FOXO1在S249位点发生磷酸化。动脉内皮细胞特异性敲除FOXO1可显著减轻高脂血症小鼠的动脉粥样硬化斑块。抑制糖酵解可阻断振荡剪切应力诱导的FOXO1核转位，而乳酸处理可促进FOXO1核定位。该效应依赖乳酰基转移酶AARS1，且与FOXO1乳酰化修饰相关。结论：本研究发现FOXO1通过乳酸驱动的乳酰化修饰与核转位，成为连接促动脉粥样硬化血流与内皮炎症基因表达的关键介质，进而促进动脉粥样硬化发生。相反，生理性流体剪切应力通过KLF2-CDK2信号抑制FOXO1。这些互补通路为动脉粥样硬化性心血管疾病提供了潜在的新型治疗靶点。短期空气污染暴露增加高血压及其多器官并发症死亡率：一项中国210万死亡病例的病例交叉研究期刊：J Am Coll CardiolPMID：41739011 简述：本项全国性、个体水平、时间分层病例交叉研究，纳入中国内地2013-2019年超210万例高血压相关死亡病例，量化短期空气污染与不同进展阶段高血压死亡风险及疾病负担的关联。结果显示污染物暴露与高血压死亡呈近似线性关系，心肾合并衰竭患者风险最高，NO₂关联最强，女性、老年等人群更易感，为高血压患者精准环境健康管理提供依据。摘要翻译: 背景短期空气污染暴露是已知的心血管事件触发因素，但该风险在高血压患者不同疾病进展阶段的变化尚不明确。目的本研究旨在量化与空气污染相关的、不同进展阶段高血压疾病的死亡风险及疾病负担。方法本研究开展全国性、个体水平、时间分层病例交叉研究，纳入中国内地2013-2019年超210万例高血压相关死亡病例。采用1×1km高分辨率时空模型估算细颗粒物（PM₂.₅）、可吸入颗粒物（PM₁₀）、二氧化氮（NO₂）及臭氧（O₃）的日均浓度，通过条件logistic回归量化关联。结果研究观察到清晰的阶梯式风险梯度。滞后0-2天（平均滞后0-2天）时，PM₂.₅每增加一个四分位距，死亡风险从单纯原发性高血压的1.39%（95%CI 0.55%-2.24%），升至高血压性心脏病的2.62%（95%CI 2.20%-3.05%）、高血压肾病的3.03%（95%CI 1.53%-4.56%），合并心肾衰竭的高血压心肾病患者达5.01%（95%CI 1.96%-8.16%）。该高危表型的归因分数也最高，4.20%（95%CI 3.55%-4.85%）的死亡可归因于PM₂.₅。此外，4种空气污染物中NO₂始终表现出最强的关联。所有4种污染物的暴露-反应曲线与高血压死亡均呈近似线性关系，无明显阈值证据。女性、≥65岁、北方居住、受教育程度较低、无配偶支持的高血压患者，以及寒冷季节的患者更易感。结论空气污染作为急性应激因素作用于高血压患者，形成由合并症严重程度决定的死亡风险梯度。研究结果强调需开展针对性风险分层，将合并心肾衰竭患者列为精准环境健康预警与靶向临床管理的优先人群。通心络胶囊干预冠状动脉粥样硬化斑块：一项多中心、随机、双盲、安慰剂对照研究期刊：Signal Transduct Target TherPMID：41735255 简述：本多中心、随机、双盲、安慰剂对照试验，旨在探究他汀治疗基础上，通心络胶囊能否提升急性冠脉综合征患者冠脉斑块稳定性。结果显示，治疗12个月后，通心络组冠脉斑块最小纤维帽厚度显著高于安慰剂组，纤维帽厚度增幅、脂质弧降幅均更优，且心绞痛症状明显改善，未降低心血管不良事件发生率。摘要翻译: 目前缺乏中药通心络胶囊治疗冠脉斑块易损性的临床证据。为探究在他汀治疗基础上，通心络能否提升急性冠脉综合征入院患者的冠脉斑块稳定性，本研究开展通心络胶囊多中心、随机、双盲临床试验。纳入经光学相干断层扫描检测存在冠脉薄帽富脂斑块的患者，在指南指导治疗基础上，按1:1比例随机分配接受通心络或安慰剂治疗12个月。主要终点为12个月后通心络组与安慰剂组患者经光学相干断层扫描评估的病变最小纤维帽厚度差异。最终共招募并随机化220例患者。主要终点方面，两组基线最小纤维帽厚度无差异，12个月随访时通心络组较安慰剂组显著升高（115.0μm vs 80.0μm，P<0.001）。通心络组最小纤维帽厚度增幅（61.2μm vs 33.7μm，P=0.002）、最大脂质弧降幅（-38.4° vs -8.1°，P=0.007）均显著优于安慰剂组。与安慰剂组相比，通心络组患者西雅图心绞痛问卷评分及加拿大心血管学会心绞痛分级均得到改善。综上，在他汀治疗基础上，通心络可增加急性冠脉综合征患者冠脉薄帽富脂斑块的纤维帽厚度、减小脂质弧并改善心绞痛症状，随访12个月未降低心血管不良事件发生率。从纤维结构到功能附着：一种临床相关、力学可调的心脏补片期刊：Adv MaterPMID：41715270 简述：本研究开发出具有多区域微结构的个性化宏观心脏补片平台，包含细胞排列再生区、应力传递刚性力传导区与弹性整合附着区，通过熔融电写技术制备，力学性能可模拟天然心肌，心外膜缝合固定能力提升2.16倍，细胞培养可显著改善心肌细胞排列，猪心梗模型中7天内完成完整心外膜附着与血管长入，证实熔融电写技术可定制心脏支架力学特性，支持组织整合与心功能修复。摘要翻译: 可收缩的工程化心脏补片作为生物心室辅助装置，在心肌梗死治疗中具有巨大潜力。然而，心脏补片的优化设计与附着方式尚未得到充分研究，而二者均是受损心脏机械支持的关键。本研究提出一种个性化宏观补片平台，具备多区域微结构，整合了促进细胞排列的再生区、负责应力传递的刚性力传导区，以及实现组织整合的弹性附着区。基于计算模型，通过定制化G代码生成器采用熔融电写技术实现该设计。数字图像相关技术显示，生理形变下支架不同区域的应变差异可达2.6倍，证实区域间协同作用。经预处理的双轴测试表明，支架力学性能可模拟天然心肌在10%应变内的特性。针对心外膜缝合固定，强化边缘设计可实现形态适配，缝合滞留力提升2.16倍。包埋纤维蛋白与心肌细胞的动态生物心室辅助装置培养，较对照组显著改善细胞排列（P=0.01）。最终，在猪心肌梗死模型中，该生物心室辅助装置7天内实现完整心外膜附着与血管长入，而对照组仅为部分附着。本研究证实熔融电写是多功能平台，可定制心脏支架力学特性，支持组织整合与心功能修复。全球冠状动脉疾病诊断成像的辐射剂量期刊：JAMAPMID：41739468 简述：本项全球横断面研究纳入101个国家742个中心的19302名冠心病无创诊断成像患者，评估不同检查模态的辐射有效剂量。结果显示不同模态、地区、国家收入水平的辐射剂量差异显著，核医学检查达标率高于冠脉CT血管造影，中低收入国家辐射剂量显著更高，亟需全球范围内的培训、标准化流程与设备更新降低辐射暴露。摘要翻译: 重要性近几十年来，全球冠状动脉疾病诊断检查显著增加，多种常用成像模态会使患者暴露于电离辐射。目的评估全球范围内接受冠状动脉疾病无创诊断检查患者的辐射剂量。设计、研究场所与研究对象本项全球横断面研究于2023年开展，纳入2023年10-12月单周内101个国家742个中心的19302名接受冠状动脉疾病无创诊断检查的成年连续患者。暴露因素受试者接受单光子发射计算机断层扫描、正电子发射断层扫描核素心脏成像、冠状动脉钙化积分心脏计算机断层扫描或冠脉计算机断层扫描血管造影检查。主要结局与指标主要结局为患者辐射有效剂量，以及中位有效剂量≤9mSv（指南推荐）的中心比例。结果 19302例患者中，女性8515例（44%），中位年龄63岁（四分位距54-71岁）。不同诊断模态的有效剂量差异显著，冠状动脉钙化积分中位有效剂量1.2mSv（四分位距0.7-2.2），正电子发射断层扫描2.0mSv（1.6-2.4），单光子发射计算机断层扫描6.5mSv（3.9-8.6），冠脉计算机断层扫描血管造影7.4mSv（3.5-15.5）。核素心脏成像检查中心与患者的剂量达标率显著高于冠脉计算机断层扫描血管造影（81% vs 56%；79% vs 56%；均P<0.001）。同一检查的辐射剂量在全球地区间差异显著，西欧最低（核素心脏成像中位4.8mSv[2.3-7.3]，冠脉计算机断层扫描血管造影4.6mSv[2.4-9.8]），核素心脏成像以拉丁美洲最高（7.8mSv[5.3-9.7]），冠脉计算机断层扫描血管造影以非洲最高（25.2mSv[14.7-35.3]）（均P<0.001）。回归模型显示，国家收入水平与辐射剂量呈负相关。中低收入国家核素心脏成像患者剂量较高收入国家高20%（95%CI 3.6%-38.4%），中低收入国家冠脉计算机断层扫描血管造影患者剂量较高收入国家高96%（95%CI 41.7%-170.8%）（均P<0.001）。同一收入水平与全球地区内部也存在显著剂量差异。结论与意义鉴于全球冠心病发病率持续上升，诊断检查辐射剂量的显著差异表明，全球亟需开展培训、标准化流程与设备更新以降低辐射暴露，中低收入国家及接受冠脉计算机断层扫描血管造影检查的患者受影响尤为显著。全球冠心病诊断质量存在重要的提升空间。用于动脉粥样硬化诊疗的空间提示、序贯激活DNA纳米装置：通过精准靶向病变巨噬细胞实现期刊：J Am Chem SocPMID：41733357 简述：本研究构建空间特异性响应的智能DNA纳米装置ASfindaCure，靶向动脉粥样硬化关键致病巨噬细胞，整合膜蛋白、微环境及细胞内生物标志物实现序贯激活，通过荧光与光声双模态成像无创评估病变进展，在细胞与小鼠模型中有效递送寡核苷酸药物，显著抑制斑块进展与炎症，为动脉粥样硬化下一代诊疗技术提供新型智能纳米平台。摘要翻译: 动脉粥样硬化是心血管疾病的主要诱因，巨噬细胞是其发病机制的关键驱动因素。研发靶向巨噬细胞、有效缓解动脉粥样硬化且最小化全身效应的治疗手段仍面临挑战。本研究提出一种精准时空特异性响应的DNA纳米结构（ASfindaCure），用于动脉粥样硬化智能诊疗。为精准靶向致动脉粥样硬化巨噬细胞，本研究利用膜蛋白SIRPα、微环境提示物凝血酶及两种细胞内生物标志物APE1、microRNA-155的空间特异性表达模式。借助结构与动态DNA纳米技术，ASfindaCure通过可编程反应级联，时序性识别这些空间分布的生物标志物。通过荧光与光声双模态成像，证实ASfindaCure可精准靶向致病巨噬细胞，为无创评估动脉粥样硬化进展提供方法。在细胞与小鼠模型中，ASfindaCure可有效向靶细胞递送microRNA-33反义寡核苷酸，显著缓解斑块进展与炎症。该智能诊疗纳米平台为下一代动脉粥样硬化治疗技术的研发提供巨大潜力，同时可应用于其他疾病领域。

2026-02-26

·北京医学感染与传染研究

临床传染病学 82卷1-2期、增刊1期（2026年2月26日更新）

Clinical Infectious Diseases Volume 82 Issue 1 临床传染病学 82卷1期 https://academic.oup.com/cid/issue/ ID Art Through the Ages（穿越时代的传染病学技艺） 1 Peasants' Revolt, 1381 1381年农民起义 Mary Grizzard and Michael Grizzard Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Page i, https://doi.org/10.1093/cid/ciaf692 In the Literature（文献概览） 2 In the Literature 文献概览 Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages ii–iii, https://doi.org/10.1093/cid/ciaf631 State-of-the-Art Review（最新技术综述） 3 State-of-the-Art Review: Diagnosis and Management of Acute and Chronic Bacterial Prostatitis 最新技术综述：急性和慢性细菌性前列腺炎的诊断与治疗 Prathit A Kulkarni and others Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 1–13, https://doi.org/10.1093/cid/ciaf483 Clinical Dilemmas in Infectious Diseases（传染病临床难题） 4 “Insisting on Treatment” “坚持治疗” Kevin Andrew Smith and others Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 14–18, https://doi.org/10.1093/cid/ciaf282 Voices of ID（传染病之声） 5 Martin Arrowsmith and Me 马丁·阿罗史密斯与我 Janet R Gilsdorf Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 19–20, https://doi.org/10.1093/cid/ciaf277 Invited Commentary（特邀述评） 6 The 2025 Centers for Disease Control and Prevention Nonoccupational HIV Postexposure Prophylaxis Guidelines: Updated Regimens and Remaining Questions 2025年美国疾病控制与预防中心非职业性艾滋病毒暴露后预防指南：更新方案及遗留问题 Lao-Tzu Allan-Blitz and Kenneth H Mayer Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 21–24, https://doi.org/10.1093/cid/ciaf567 Antimicrobial Resistance and Stewardship（抗菌药物耐药性与管控） 7 Modeling the Impact and Cost of a Culture-Dependent Molecular Test for Antimicrobial Resistance in Resource-Limited Settings 资源有限环境下，基于培养的分子检测法对抗菌药物耐药性的影响和成本建模 Joshua M Chevalier and others Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 25–32, https://doi.org/10.1093/cid/ciaf236 8 The Xpert MTB/RIF Cycle Threshold Value Predicts Mycobacterium tuberculosis Transmission to Close Contacts in a Brazilian Prospective Multicenter Cohort 巴西一项前瞻性多中心队列研究中Xpert MTB/RIF循环阈值可预测结核分枝杆菌在密切接触者中的传播 Leandro S Garcia and others Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 33–41, https://doi.org/10.1093/cid/ciad794 9 Beyond Diagnosis: Xpert Cycle Threshold Values as Predictors of Tuberculosis Transmission 超越诊断：Xpert循环阈值作为结核病传播的预测指标 Lauren Linde and others Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 42–43, https://doi.org/10.1093/cid/ciad791 10 First Report of Treatment-Emergent Resistance to Cefepime-Zidebactam in Pseudomonas aeruginosa 铜绿假单胞菌在头孢吡肟-齐德巴坦治疗中出现耐药性的首例报告 Ava J Dorazio and others Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 44–48, https://doi.org/10.1093/cid/ciaf638 Clinical Practice and Policy（临床实践与政策） 11 Sputum and Tongue Swab Molecular Testing for the In-Home Diagnosis of Tuberculosis in Unselected Household Contacts: A Cost and Cost-Effectiveness Analysis 痰液和舌拭子分子检测用于未筛选家庭接触者结核病居家诊断的成本及成本效益分析 Charl Bezuidenhout and others Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 49–57, https://doi.org/10.1093/cid/ciaf389 12 You’ve Got a Friend in Me: Curbside Questions Infectious Diseases Clinicians Ask Infectious Diseases Pharmacists 我是你的朋友：传染病临床医生向传染病药剂师咨询的即兴问题 Matthew R Davis and others Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 58–61, https://doi.org/10.1093/cid/ciaf250 13 Home Testing for Contagious Illness: Historical Context and Modern Caveats 传染性疾病居家检测：历史背景与现代注意事项 Abigail Zuger Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 62–66, https://doi.org/10.1093/cid/ciaf623 Fungal Infections（真菌感染） 14 Evaluating the Use of Lower Dose Flucytosine for the Treatment of Cryptococcal Meningitis: A Clinical Trial 评估低剂量氟胞嘧啶治疗隐球菌性脑膜炎的临床试验 Morris K Rutakingirwa and others Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 67–74, https://doi.org/10.1093/cid/ciaf432 15 Association Between Duration of Candidemia and Clinical and Healthcare Resource Utilization Outcomes Among Hospitalized Adult Patients With Candidemia Who Received Empiric Treatment With an Echinocandin Across United States Hospitals 美国各医院中接受棘白菌素经验性治疗的念珠菌血症成年住院患者中，念珠菌血症持续时间与临床和医疗资源利用结局之间的关联 Thomas P Lodise and others Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 75–85, https://doi.org/10.1093/cid/ciaf472 16 Aspergillosis-Attributable Mortality in the United States: Analysis of Death Certificate Data 美国隐球菌病导致的死亡率分析：基于死亡证明数据 Thomas J Walsh and others Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 86–92, https://doi.org/10.1093/cid/ciaf653 HIV/AIDs（人类免疫缺陷病毒/艾滋病） 17 Outcomes of Critical Illness in People With Advanced HIV Disease: 30 Years of Binational Data 晚期艾滋病患者危重症结局：30年的双国数据 Bryan Tan and others Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 93–99, https://doi.org/10.1093/cid/ciaf362 18 Phase 2 Trial of Long-Acting Cabotegravir and VRC07-523LS for Viral Suppression in Adults With HIV-1: ACTG A5357 长效卡博特韦和VRC07-523LS用于HIV-1感染成人病毒抑制的2期试验：ACTG A5357 Babafemi O Taiwo and others Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 100–108, https://doi.org/10.1093/cid/ciaf375 19 Therapeutic Drug Monitoring of Long-Acting Cabotegravir and Rilpivirine in a National Cohort of People With HIV-1: First Results From the ANRS-MIE CARLAPOP Study 全国HIV-1感染者队列中长效卡博特韦和利匹韦林的治疗药物监测：ANRS-MIE CARLAPOP研究的首批结果 Nadège Néant and others Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 109–118, https://doi.org/10.1093/cid/ciaf385 20 Is Therapeutic Drug Monitoring of Long-Acting Cabotegravir and Rilpivirine of Clinical Utility? 长效卡博特韦和利匹韦林的治疗药物监测是否具有临床实用性？ Catia Marzolini Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 119–121, https://doi.org/10.1093/cid/ciaf386 21 Efficacy and Safety of Dual Therapy With Dolutegravir/Lamivudine in Treatment-naive Persons With CD4 Counts <200/mm3: 48-Week Results of the DOLCE Study 多替拉韦/拉米夫定双药治疗在CD4计数<200/mm³的初治患者中的疗效和安全性：DOLCE研究48周结果 Maria Ines Figueroa and others Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 122–131, https://doi.org/10.1093/cid/ciaf415 22 DOLCE: Sweet Success for Dolutegravir/Lamivudine? DOLCE研究：多替拉韦/拉米夫定双药治疗是否取得完美成功？ Laura J Waters Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 132–133, https://doi.org/10.1093/cid/ciaf416 Infection Control and Hospital Epidemiology（感染控制与医院流行病学） 23 Real-Time Genomic Surveillance for Enhanced Healthcare Outbreak Detection and Control: Clinical and Economic Impact 实时基因组监测用于加强医疗保健机构疫情检测与控制：临床与经济影响 Alexander J Sundermann and others Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 134–141, https://doi.org/10.1093/cid/ciaf216 24 Patient Perspectives Regarding Different Contact Precaution Policies for Methicillin-resistant Staphylococcus aureus Across Two Hospitals: Patients Are in Favor of Contact Precautions 两家医院患者对耐甲氧西林金黄色葡萄球菌不同接触预防政策的态度：患者支持接触预防措施 Nicholas F Angelino and others Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 142–144, https://doi.org/10.1093/cid/ciaf330 Photo Quiz（影像问答） 25 The Clue That Wriggled into View 蜿蜒入目的线索 Nitin Gupta and others Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 145–147, https://doi.org/10.1093/cid/ciaf427 Infection Control and Hospital Epidemiology（感染控制与医院流行病学） 26 Comparing Generative Artificial Intelligence vs Experts for Detection of Catheter-Associated Urinary Tract Infection 比较生成式人工智能与专家在导管相关尿路感染检测中的应用 Shatha Alshanqeeti and others Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 148–150, https://doi.org/10.1093/cid/ciaf486 Sexually Transmitted Infections（性传播感染） 27 Viability of Chlamydia trachomatis in Different Anatomical Sites—a Systematic Review and Meta-analysis 不同解剖部位沙眼衣原体的存活能力——系统综述和荟萃分析 Arthur Wong and others Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 151–158, https://doi.org/10.1093/cid/ciae401 Photo Quiz（影像问答） 28 A 46-Year-Old With Persistent Altered Mental Status and Respiratory Failure 一例46岁患者持续出现意识状态改变伴呼吸衰竭 Ann F Yang and others Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 159–161, https://doi.org/10.1093/cid/ciaf439 Sexually Transmitted Infections（性传播感染） 29 Mpox in People With HIV: Predictors of Diagnosis, Outcomes, and Vaccine Effectiveness in a Multisite Cohort HIV感染者中的猴痘：多站点队列中诊断、预后和疫苗有效性的预测因素 Michalina Montaño and others Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 162–172, https://doi.org/10.1093/cid/ciae464 30 Development and Evaluation of a Novel Algorithm to Identify Doxycycline Postexposure Prophylaxis Users at a Large Healthcare System in the Bronx, New York 开发和评估一种新型算法，用于识别纽约布朗克斯区一家大型医疗系统中多西环素暴露后预防用药者 Caroline E Mullis and others Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 173–176, https://doi.org/10.1093/cid/ciaf109 31 Evidence-Informed Provision of Doxycycline Postexposure Prophylaxis for Prevention of Bacterial Sexually Transmitted Infections 为预防细菌性性传播感染提供基于证据的多西环素暴露后预防用药 Julia C Dombrowski and others Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 177–184, https://doi.org/10.1093/cid/ciae527 Bacterial Infections（细菌性感染） 32 Long-term Mortality Trends Among Individuals With Tuberculosis: A Retrospective Cohort Study of Individuals Diagnosed With Tuberculosis in Brazil 巴西结核病患者的长期死亡率趋势：一项针对巴西结核病诊断患者的回顾性队列研究 Sun Kim and others Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e1–e8, https://doi.org/10.1093/cid/ciaf206 33 Clinical and Microbiological Characteristics of Meningococcal Eye Infections: Retrospective National Surveillance in England, 2010–2022 脑膜炎球菌眼部感染的临床和微生物学特征：2010 - 2022年英格兰全国回顾性监测 Stephen A Clark and others Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e9–e16, https://doi.org/10.1093/cid/ciaf274 34 Does Piperacillin-Tazobactam Increase Mortality Risk Compared With Cefepime? Collider Bias and the Importance of Assumptions in Instrumental Variable Analyses 与头孢吡肟相比，哌拉西林-他唑巴坦是否会增加死亡率风险？工具变量分析中的混杂偏倚和假设的重要性 Fergus Hamilton and others Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e17–e23, https://doi.org/10.1093/cid/ciaf317 COVID-19 / SARS COV-2（新冠肺炎/严重急性呼吸综合征冠状病毒2型） 35 Efficacy and Safety of Obeldesivir in High-Risk Nonhospitalized Patients With COVID-19 (BIRCH): A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study 奥贝德西韦在高危非住院COVID-19患者（BIRCH研究）中的疗效和安全性：一项3期、随机、双盲、安慰剂对照研究 Anca Streinu-Cercel and others Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e24–e32, https://doi.org/10.1093/cid/ciaf406 36 Retreatment With Nirmatrelvir/Ritonavir Following Return of COVID-19 Symptoms and SARS-CoV-2 Positivity COVID-19症状复发且SARS-CoV-2检测呈阳性后使用奈玛特韦/利托那韦重新治疗 Wuyan Zhang and others Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e33–e40, https://doi.org/10.1093/cid/ciaf548 Emerging Infections(新兴感染) 37 “I Didn’t Know Him Before the Pandemic… Now He's on My Speed Dial”: Strengthening Collaboration Between Infectious Diseases Physicians and State and Local Public Health for Future Public Health Emergencies “疫情前我并不认识他……现在他已是我的快速拨号对象”：加强传染病医生与州和地方公共卫生部门在未来突发公共卫生事件中的合作 Diana Valencia and others Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e41–e46, https://doi.org/10.1093/cid/ciaf179 38 Identification of and Response to Influenza A(H5) in Off-the-Shelf Raw Milk—Santa Clara County, California, November–December 2024 2024年11 - 12月加利福尼亚州圣克拉拉县在现成生牛奶中检出甲型流感（H5）病毒及应对措施 Alessandra Løchen and others Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e47–e48, https://doi.org/10.1093/cid/ciaf420 39 The Indispensable Value of Small-Molecule Antivirals in Epidemic and Pandemic Preparedness 小分子抗病毒药物在流行病和大流行病防范中的不可或缺价值 Ruxandra Draghia-Akli and others Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e49–e55, https://doi.org/10.1093/cid/ciaf476 HIV/AIDs（人类免疫缺陷病毒/艾滋病） 40 Increasing HIV Testing During Gonorrhea and Chlamydia Evaluations in Urgent Care and Emergency Departments: A Large Health System Initiative 在紧急护理和急诊科进行淋病和衣原体检测时增加HIV检测：一项大型医疗系统倡议 Allan M Seibert and others Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e56–e67, https://doi.org/10.1093/cid/ciaf434 41 Clinical Predictors and Incidence of Kaposi Sarcoma Among Males With HIV in the Treat-All Era in the United States and Canada 美国和加拿大“全员治疗”时代男性HIV感染者卡波西肉瘤的临床预测因素和发病率 Sally B Coburn and others Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e68–e77, https://doi.org/10.1093/cid/ciaf446 42 Integrase Strand Transfer Inhibitors for Treatment-experienced Young Adults With Perinatal HIV in the US: Immunologic, Virologic, and Anthropometric Outcomes 美国接受过治疗的围产期感染HIV的年轻成人使用整合酶链转移抑制剂的免疫学、病毒学和人体测量学结果 Kunjal Patel and others Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e78–e88, https://doi.org/10.1093/cid/ciaf538 43 Win Ratio Aligns With and Enhances Interpretation of REPRIEVE's Primary Findings Win比值与REPRIEVE研究的主要发现一致并增强了其解释性 Emma Davies Smith and others Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e89–e92, https://doi.org/10.1093/cid/ciaf477 44 The Critical Importance of Clinical Use Case to Inform Point-of-Care Technology Development: A Case Study of HIV Nucleic Acid Assays in the United States 临床应用案例对于指导即时检测技术开发的重要性：以美国HIV核酸检测为例 Yukari C Manabe and others Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e93–e99, https://doi.org/10.1093/cid/ciaf510 Mycobacterial Infections（分枝杆菌感染） 45 Body Mass Index and Incident Tuberculosis in Close Tuberculosis Contacts 结核密切接触者中体重指数与新发结核病的关系 María B Arriaga and others Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e100–e109, https://doi.org/10.1093/cid/ciaf475 46 The Role of Youths in Within-Household Tuberculosis Transmission: A Household Contact Cohort Study 青年在家庭内结核病传播中的作用：一项家庭接触队列研究 Meredith B Brooks and others Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e110–e118, https://doi.org/10.1093/cid/ciaf490 47 Cost-effectiveness of Targeted Next-Generation Sequencing for Tuberculosis Drug-resistance Testing as an Alternative to the Standard of Care in South Africa 南非以靶向下一代测序作为结核病耐药检测标准护理方案的替代方案的成本效益分析 Alexandra de Nooy and others Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e119–e125, https://doi.org/10.1093/cid/ciaf495 48 Xpert MTB/RIF Cycle Threshold as a Marker of Tuberculosis (TB) Disease Severity: Implications for TB Treatment Stratification Xpert MTB/RIF循环阈值作为结核病（TB）疾病严重程度的标志物：对结核病治疗分层的启示 Daniel J Grint and others Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e126–e134, https://doi.org/10.1093/cid/ciaf527 49 The Role of β-Lactam Antibiotics in Treating Mycobacterium abscessus: From Laboratory Insights to Clinical Applications and the Case for Clinical Trials β-内酰胺类抗生素在治疗脓肿分枝杆菌中的作用：从实验室见解到临床应用及开展临床试验的必要性 Khalid M Dousa and others Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e135–e145, https://doi.org/10.1093/cid/ciaf547 Pediatric and Maternal Infectious Diseases（儿科与孕产妇传染病） 50 Efficacy, Immunogenicity, and Safety of an Investigational Maternal Respiratory Syncytial Virus Prefusion F Protein–Based Vaccine 一种研究性孕产妇呼吸道合胞病毒融合前F蛋白疫苗的疗效、免疫原性和安全性 Peyman Banooni and others Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e146–e155, https://doi.org/10.1093/cid/ciaf033 51 Hepatotoxicity Among People With HIV and Receiving Isoniazid Preventive Therapy in Pregnancy and Postpartum: The Role of Antiretroviral Regimen and Pharmacogenetics HIV感染者在孕期和产后接受异烟肼预防性治疗时的肝毒性：抗逆转录病毒治疗方案和药物基因组学的作用 Grace Montepiedra and others Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e156–e164, https://doi.org/10.1093/cid/ciaf198 52 Transplacental Transfer of Lumefantrine, Mefloquine, and Piperaquine: A Comparison of Concentrations in Mothers, Neonates, and Cord Blood 青蒿素、甲氟喹和哌喹的胎盘转运：母亲、新生儿和脐带血中浓度的比较 Makoto Saito and others Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e165–e173, https://doi.org/10.1093/cid/ciaf552 53 Why Did the Antimalarial Drug Cross the Placenta? 抗疟药为何要穿过胎盘？ Stephen J Rogerson and Holger W Unger Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e174–e175, https://doi.org/10.1093/cid/ciaf553 Viral Infections（病毒性传染病） 54 Kinetics and Predictors of Hepatitis B Surface Antigen Loss After Commencing Hepatitis B Virus (HBV)–Active Antiretroviral Therapy in the Setting of HIV and Chronic HBV Coinfection HIV和慢性乙型肝炎病毒（HBV）共感染患者开始使用HBV活性抗逆转录病毒治疗后乙型肝炎表面抗原消失的动力学和预测因素 Jennifer Audsley and others Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e176–e184, https://doi.org/10.1093/cid/ciaf281 55 Secondary Pneumococcal Disease in Veterans With Viral Respiratory Infections 患有病毒性呼吸道感染退伍军人的继发性肺炎球菌病 Lauren A Powers and others Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e185–e190, https://doi.org/10.1093/cid/ciaf285 Correspondence（读者来信） 56 Unveiling Latent Risk Patterns in Antimicrobial-Resistant Bacteremia: A Deeper Look at Pathogen-Specific Mortality 揭示抗菌药物耐药性菌血症中的潜在风险模式：深入探究病原体特异性死亡率 Yuan-Ti Lee and Shiuan-Chih Chen Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Page e191, https://doi.org/10.1093/cid/ciaf493 57 Resistance to Antibiotics With High Empiric Treatment Relevance Explains Attributable Mortality Across 110 Pathogen-antibiotic Combinations 对经验性治疗具有高度相关性的抗生素耐药性可解释110种病原体 - 抗生素组合的归因死亡率 Kevin A Brown and Nick Daneman Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e191–e192, https://doi.org/10.1093/cid/ciaf494 58 Culture Clash: Dual-Pathogen Endocarditis and the Metagenomic Next-Generation Sequencing Studies We Need 文化冲突：双病原体心内膜炎以及我们所需的宏基因组下一代测序研究 Carl Boodman and others Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e193–e195, https://doi.org/10.1093/cid/ciaf518 59 Metagenomic Next-Generation Sequencing and Cardiovascular Infections: Promise and Pitfalls of Polymicrobial Detection 宏基因组下一代测序与心血管感染：多微生物检测的前景与陷阱 Sarwat Khalil and M Rizwan Sohail Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Page e196, https://doi.org/10.1093/cid/ciaf519 60 It Is Time to Go Beyond the Association Between Colistin and Meropenem for Invasive Carbapenem-Resistant Acinetobacter baumannii Infections 是时候超越多粘菌素和美罗培南联合治疗侵袭性碳青霉烯耐药鲍曼不动杆菌感染了 Alberto Enrico Maraolo and Giancarlo Ceccarelli Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e197–e198, https://doi.org/10.1093/cid/ciaf533 61 Actually, It May be Time to Return to Colistin and Meropenem in Some Patients Infected With Carbapenem-resistant Acinetobacter baumannii (CRAB) 实际上，对于某些感染碳青霉烯耐药鲍曼不动杆菌（CRAB）的患者，或许是时候重新使用多粘菌素和美罗培南了 Jason M Pogue and Keith S Kaye Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e198–e199, https://doi.org/10.1093/cid/ciaf534 62 COVID-19 and Bacterial Pneumonia: Protective Effect or Diagnostic Bias? COVID-19和细菌性肺炎：保护作用还是诊断偏差？ Duygu Aydın and others Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Page e200, https://doi.org/10.1093/cid/ciaf539 63 Secondary Pneumococcal Disease in Veterans With Viral Respiratory Infections: A Follow Up 患有病毒性呼吸道感染退伍军人的继发性肺炎球菌病：后续研究 John C Hu and others Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e200–e201, https://doi.org/10.1093/cid/ciaf540 64 Long-Acting Cabotegravir/Rilpivirine in Viremic People With HIV: Bumpy Road to Perfection 长效卡博特韦/利匹韦林用于病毒载量阳性的HIV感染者：通往完美的坎坷之路 Beatrice Barda and Marco Bongiovanni Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e201–e202, https://doi.org/10.1093/cid/ciaf482 65 Beyond the Sequence: Operationalizing Whole-Genome Sequencing for Real-time Infection Control in Low- and Middle-Income-Country Healthcare Settings Healthcare Settings 超越序列：在中低收入国家医疗环境中实际应用全基因组测序进行实时感染控制 Schawanya Kaewpitoon Rattanapitoon and others Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e202–e203, https://doi.org/10.1093/cid/ciaf535 66 Reassessing Adherence Trajectories in Multidrug-Resistant Tuberculosis: Recovery Advantage and Hidden Biases 重新评估耐多药结核病的依从性轨迹：康复优势和隐藏偏差 Shiuan-Chih Chen and Chun-Chieh Chen Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e203–e204, https://doi.org/10.1093/cid/ciaf536 67 Metagenomic Sequencing of Blood Culture Broth for Diagnosing Fastidious Endocarditis 血培养肉汤宏基因组测序用于诊断苛养性心内膜炎 Po-Hsiu Huang and others Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e204–e205, https://doi.org/10.1093/cid/ciaf554 Corrections（更正） 68 Correction to: Secondary Pneumococcal Disease in Veterans With Viral Respiratory Infections 《患有病毒性呼吸道感染退伍军人的继发性肺炎球菌病》更正 Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Page e206, https://doi.org/10.1093/cid/ciaf572 69 Correction to: Treatment Outcomes With an Oral Short Course Regimen for Rifampicin-resistant Tuberculosis in a High HIV Prevalence, Programmatic Setting in South Africa 《南非高HIV流行率、项目化环境中口服短程利福平耐药结核病治疗方案的治疗结果》更正 Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Page e207, https://doi.org/10.1093/cid/ciaf711 Clinical Infectious Diseases Volume 82 Issue Supplement_1 临床传染病学 82卷增刊1期 https://academic.oup.com/cid/issue/82/Supplement_1 SUPPLEMENT（增刊） Laboratory and Point-of-care Testing to Detect Chlamydia trachomatis and Neisseria gonorrhoeae: Review of the Available Evidence 实验室及即时检测技术用于检测沙眼衣原体和淋病奈瑟菌：现有证据综述 SUPPLEMENT ARTICLES（增刊论著） 1 Evidence Review for Centers for Disease Control and Prevention Guidance Development on the Detection of Chlamydia trachomatis and Neisseria gonorrhoeae 美国疾病控制与预防中心沙眼衣原体和淋病奈瑟菌检测指南制定证据综述 Amanda C Smith and Ellen N Kersh Clinical Infectious Diseases, Volume 82, Issue Supplement_1, 15 February 2026, Pages S1–S5, https://doi.org/10.1093/cid/ciaf665 2 Narrative Review of Chlamydia trachomatis Culture, Viability Testing, and Sequencing Methods 沙眼衣原体培养、活性检测及测序方法的叙述性综述 Alana K Sterkel and others Clinical Infectious Diseases, Volume 82, Issue Supplement_1, 15 February 2026, Pages S6–S12, https://doi.org/10.1093/cid/ciaf697 3 Culture and Identification of Neisseria gonorrhoeae: A Narrative Review of Current Laboratory Methods 淋病奈瑟菌培养与鉴定：当前实验室方法叙述性综述 Olusegun O Soge and others Clinical Infectious Diseases, Volume 82, Issue Supplement_1, 15 February 2026, Pages S13–S18, https://doi.org/10.1093/cid/ciaf698 4 Review of the Performance of Laboratory-Based Molecular Diagnostics for Chlamydia trachomatis and Neisseria gonorrhoeae 实验室分子诊断技术检测沙眼衣原体和淋病奈瑟菌的性能综述 Megan Crumpler and others Clinical Infectious Diseases, Volume 82, Issue Supplement_1, 15 February 2026, Pages S19–S35, https://doi.org/10.1093/cid/ciaf696 5 Review of Methods for Detecting Antimicrobial Resistance of Neisseria gonorrhoeae 淋病奈瑟菌抗菌药物耐药性检测方法综述 Kara K Mitchell and others Clinical Infectious Diseases, Volume 82, Issue Supplement_1, 15 February 2026, Pages S36–S42, https://doi.org/10.1093/cid/ciaf706 6 Point-of-care Tests for Chlamydia trachomatis and Neisseria gonorrhoeae: Review of the Literature 沙眼衣原体和淋病奈瑟菌即时检测技术文献综述 Yukari C Manabe and others Clinical Infectious Diseases, Volume 82, Issue Supplement_1, 15 February 2026, Pages S43–S51, https://doi.org/10.1093/cid/ciaf699 Clinical Infectious Diseases Volume 82 Issue 2 临床传染病学 82卷 2期 https://academic.oup.com/cid/issue/ ID Art Through the Ages（穿越时代的传染病技艺） 1 Interior of the Old Jersey Prison Ship in the Revolutionary War 美国革命战争中老泽西监狱船的内部景象 Mary Grizzard and Michael Grizzard Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Page i, https://doi.org/10.1093/cid/ciaf693 In the Literature（本期精选） 2 In the Literature 本期精选 Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages ii–v, https://doi.org/10.1093/cid/ciag011 IDSA 2025 Collections Editorial（美国传染病学会2025年专题合集社论） 3 2025 Content Collections from the IDSA Journals IDSA期刊2025年内容合集 Roger Bedimo and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 185–186, https://doi.org/10.1093/cid/ciag041 State-of-the-Art Review（前沿综述） 4 State-of-the-Art Review: Chagas Disease—an Enduring Challenge 前沿综述：恰加斯病——一个持续存在的挑战 Nelson Iván Agudelo Higuita and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 187–205, https://doi.org/10.1093/cid/ciaf654 IDSA Features（美国传染病学会特色内容） 5 Policy Recommendations to Support Equitable Access to Long-Acting Injectables for HIV Prevention and Treatment: A Policy Paper of the Infectious Diseases Society of America and the HIV Medicine Association 支持公平获取用于艾滋病毒预防和治疗的长效注射剂的政策建议：美国传染病学会与艾滋病毒医学协会的政策文件 Julia L Marcus and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 206–211, https://doi.org/10.1093/cid/ciae648 Voices of ID（传染病之声） 6 A “Terminal Infection” “绝症感染” Jennifer Furin Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 212–214, https://doi.org/10.1093/cid/ciaf332 Invited Commentary（特邀评论） 7 A Rapid Test to Differentiate Viral From Bacterial Infections: Searching for the Holy Grail 区分病毒与细菌感染的快速检测：寻找“圣杯” Lao-Tzu Allan-Blitz and Jeffrey D Klausner Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 215–218, https://doi.org/10.1093/cid/ciaf585 Bacterial Infections（细菌感染） 8 Nonoperative Versus Neurosurgical Treatment of Brain Abscess: An Emulated Trial Nested Within a Nationwide, Population-Based Cohort 脑脓肿的非手术治疗与神经外科治疗：一项基于全国人群队列的模拟试验 Emilie Marie Eriksen and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 219–227, https://doi.org/10.1093/cid/ciaf304 9 What Is the Impact of Anti-Enterococcal Empirical Therapy on Survival of Patients With Enterococcal Bloodstream Infections? 抗肠球菌经验性治疗对肠球菌血流感染患者生存率的影响是什么？ Linda Bussini and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 228–237, https://doi.org/10.1093/cid/ciaf323 10 Adjunctive Fosfomycin for the Treatment of Staphylococcus aureus Bacteremia: A Pooled Post Hoc Analysis of Individual Participant Data From 2 Randomized Trials 辅助使用磷霉素治疗金黄色葡萄球菌菌血症：两项随机试验个体参与者数据的汇总事后分析 Francesc Escrihuela-Vidal and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 238–245, https://doi.org/10.1093/cid/ciaf387 HIV/AIDs（人类免疫缺陷病毒/艾滋病） 11 Kinetics of Non-nucleoside Reverse Transcriptase Inhibitor Resistance-associated Mutations in HIV-1 Proviral Cellular Reservoirs in Non-nucleoside Reverse Transcriptase Inhibitor-experienced Persons 在接受过非核苷类逆转录酶抑制剂治疗的HIV-1感染者中，非核苷类逆转录酶抑制剂耐药相关突变在HIV-1前病毒细胞储存库中的动力学 Thomas Drumel and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 246–251, https://doi.org/10.1093/cid/ciaf430 12 Impact of Different Integrase Strand Transfer Inhibitors on Body Mass Index Among People With HIV Who Newly Started Antiretroviral Therapy in Shenzhen, China: A Real-World Data Analysis 中国深圳新开始抗逆转录病毒治疗的HIV感染者使用不同整合酶链转移抑制剂对体重指数的影响：一项现实数据分析 Lukun Zhang and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 252–261, https://doi.org/10.1093/cid/ciaf466 13 Consequences of Stopping Antiretroviral Treatment in a Persistently Seronegative Individual with HIV-1 HIV-1持续血清阴性个体停止抗逆转录病毒治疗的后果 Marc Wirden and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 262–264, https://doi.org/10.1093/cid/ciaf422 14 Approaches to the Management of Virologic Failure on Dolutegravir-Based Antiretroviral Therapy in the 50 Countries With the Highest Adult HIV Prevalence 在成人HIV患病率最高的50个国家中，多替拉韦为基础的抗逆转录病毒治疗出现病毒学失败的治疗方法 Cameron T Nutt and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 265–273, https://doi.org/10.1093/cid/ciaf444 Mycobacterial Infections（结核分枝杆菌感染） 15 Retrospective Cohort Analysis for Identification of Discordant Rifampicin-resistant Xpert MTB/RIF Assay Results in South Kivu, Eastern Democratic Republic of the Congo, a High Burden Tuberculosis Setting 刚果民主共和国东部南基伍这一结核病高负荷地区，识别利福平耐药不一致的Xpert MTB/RIF检测结果的回顾性队列分析 Bertin C Bisimwa and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 274–281, https://doi.org/10.1093/cid/ciaf451 16 Prevention of Tuberculosis in Patients Treated With Biological Therapies: 20 Years' Experience in a Specialized Tuberculosis Clinic in a Low-prevalence Country 生物疗法治疗患者中结核病的预防：某低流行国家一个专科结核病诊所20年的经验 Sandra Pérez-Recio and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 282–290, https://doi.org/10.1093/cid/ciaf491 17 Reducing Household Tuberculosis Transmission: A Pilot Cluster-Randomized Controlled Trial 减少家庭内结核病传播：一项试点整群随机对照试验 Cinthya Ruiz-Tagle and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 291–298, https://doi.org/10.1093/cid/ciaf526 18 (Un)masking Tuberculosis （揭开）结核病的“面具” Joseph N Burzynski and Neil W Schluger Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 299–300, https://doi.org/10.1093/cid/ciaf528 19 Estimating the Accuracy and Additionality of TB-LAM to Diagnose TB in Children Without HIV (AccuLAM) 评估TB-LAM在无HIV儿童中诊断结核病的准确性和额外价值（AccuLAM） Lucía CarratalàCastro and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 301–303, https://doi.org/10.1093/cid/ciaf525 Sexually Transmitted Infections（性传播感染） 20 Potential Impact of Doxycycline Post-exposure Prophylaxis Prescribing Strategies on Incidence of Bacterial Sexually Transmitted Infections 多西环素暴露后预防用药策略对细菌性性传播感染发病率的影响 Michael W Traeger and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 304–311, https://doi.org/10.1093/cid/ciad488 21 Filling in the Gaps: Updates on Doxycycline Prophylaxis for Bacterial Sexually Transmitted Infections 填补空白：多西环素预防细菌性性传播感染的最新进展 Aniruddha Hazra and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 312–320, https://doi.org/10.1093/cid/ciae062 22 Reported Neurologic Manifestations Among Persons With Syphilis by Stage of Infection—12 States, 2019–2022 2019-2022年12个州按感染阶段划分的梅毒患者报告的神经系统表现 Sarah B Wondmeneh and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 321–325, https://doi.org/10.1093/cid/ciaf015 Viral Infections（病毒性感染） 23 Investigating the Role of Cytomegalovirus as a Cause of Stillbirths and Child Deaths in Low- and Middle-Income Countries Through Postmortem Minimally Invasive Tissue Sampling 通过死后微创组织采样，调查巨细胞病毒在低收入和中等收入国家死胎和儿童死亡原因中的作用 Sithembiso Velaphi and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 326–336, https://doi.org/10.1093/cid/ciaf098 Photo Quiz（影像问答） 24 Bursting at the Seams “撑破” Maxwell Olenski and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 337–340, https://doi.org/10.1093/cid/ciaf488 Viral Infections（病毒性感染） 25 Clinical and Epidemiological Investigation of Vaccine-Derived Poliovirus Type 2 Outbreak in Pakistan During 2019–2021 2019-2021年巴基斯坦2型疫苗衍生脊髓灰质炎病毒疫情的临床和流行病学调查 Nayab Mehmood and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 341–351, https://doi.org/10.1093/cid/ciaf151 26 Inactivated Polio Vaccine Must Be an Essential Part of Polio Eradication 灭活脊髓灰质炎疫苗必须是根除脊髓灰质炎的重要组成部分 Konstantin Chumakov and Stanley A Plotkin Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 352–353, https://doi.org/10.1093/cid/ciaf215 Photo Quiz（影像问答） 27 Intracranial Lesion in a Patient With Chronic Myeloid Leukemia 慢性髓性白血病患者颅内病变 Mohammed Shakeel Sillat and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 354–357, https://doi.org/10.1093/cid/ciaf441 Viral Infections（病毒性感染） 28 Respiratory Syncytial Virus Co-Detection With Other Respiratory Viruses Is Not Significantly Associated With Worse Clinical Outcomes Among Children Aged <2 Years: New Vaccine Surveillance Network, 2016–2020 在<2岁的婴幼儿中，呼吸道合胞病毒与其他呼吸道病毒共同检测与临床预后恶化无显著关联：2016-2020年新疫苗监测网络数据 Justin Z Amarin and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 358–365, https://doi.org/10.1093/cid/ciaf194 29 Transfer of Herpes Simplex Virus Type 1 (HSV-1) Specific T Cells in a Pediatric Patient Post-HSCT With Severe, Acyclovir-resistant HSV-1 Infection 一例异基因造血干细胞移植后严重、阿昔洛韦耐药的单纯疱疹病毒1型（HSV-1）感染患儿的HSV-1特异性T细胞的输注 Astrid Wintering and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 366–369, https://doi.org/10.1093/cid/ciaf125 Clinical Trials（临床实验） 30 Interferon-α Nasal Spray Prophylaxis Reduces COVID-19 in Cancer Patients: A Randomized, Double-Blinded, Placebo-Controlled Trial 干扰素-α鼻喷雾剂预防可降低癌症患者新冠病毒感染率：一项随机、双盲、安慰剂对照试验 Michelle K Yong and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e208–e216, https://doi.org/10.1093/cid/ciaf409 31 A Phase 3, Randomized Trial Investigating the Safety, Tolerability, and Immunogenicity of V116, an Adult-Specific Pneumococcal Conjugate Vaccine, in Pneumococcal Vaccine-Naïve Adults 18–64 Years of Age at Increased Risk of Pneumococcal Disease, STRIDE-8 一项3期随机试验，调查V116（一种成人特异性肺炎球菌结合疫苗）在未接种过肺炎球菌疫苗且患肺炎球菌疾病风险增加的18-64岁年龄段成人中的安全性、耐受性和免疫原性，STRIDE-8试验 Paul T Scott and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e217–e226, https://doi.org/10.1093/cid/ciaf604 32 Effect of Direct-from-blood Bacterial Testing on Antibiotics Administration in Adults Presenting With Acute Infection: A Randomized Trial 直接从血液进行细菌检测对急性感染成年患者抗生素给药的影响：一项随机试验 David C Gaston and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e227–e235, https://doi.org/10.1093/cid/ciaf677 33 The Tantalizing Pursuit for a Perfect Diagnostic Test: Balancing Innovation With Stewardship 对完美诊断检测的诱人追求：平衡创新与管理 K C Coffey and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e236–e238, https://doi.org/10.1093/cid/ciaf674 Global Health and Neglected Tropical Diseases（全球健康与被忽视的热带病） 34 Diagnostic Accuracy of Tuberculosis Screening Tests in a Prospective Multinational Cohort: Chest Radiography With Computer-Aided Detection, Xpert Tuberculosis Host Response, and C-Reactive Protein 在一项前瞻性多国队列研究中，结核病筛查试验的诊断准确性：计算机辅助检测的胸部X光片、Xpert结核宿主反应检测和C反应蛋白 Rebecca Crowder and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e239–e247, https://doi.org/10.1093/cid/ciae549 HIV/AIDs（人类免疫缺陷病毒/艾滋病） 35 Risk Assessment in a Global CVD Prevention Cohort of People With HIV by PCE, PREVENT, and SCORE2 通过PCE、PREVENT和SCORE2对全球心血管疾病预防队列中艾滋病毒感染者进行风险评估 Steven K Grinspoon and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e248–e257, https://doi.org/10.1093/cid/ciaf542 36 REPRIEVE Analysis of New Cardiovascular Risk Calculators in HIV: Underpredicting Risk Means Preventing Fewer Heart Attacks HIV新心血管风险计算器的REPRIEVE分析：低估风险意味着预防的心脏病发作更少 Matthew S Durstenfeld Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e258–e261, https://doi.org/10.1093/cid/ciaf543 37 Comparable Inflammatory and Metabolic Outcomes After Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Continuing Dolutegravir/Lamivudine in Virologically Suppressed Adults With HIV (INSTINCT/GESIDA10918 Study) 在病毒学抑制的HIV感染成人中，转换为比克替拉韦/恩曲他滨/丙酚替诺福韦与继续使用多替拉韦/拉米夫定后的炎症和代谢结局相当（INSTINCT/GESIDA10918研究） Sergio Serrano-Villar and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e262–e274, https://doi.org/10.1093/cid/ciaf565 38 Tenofovir Alafenamide and Body Weight: Have We Finally Tipped the Scale? 丙酚替诺福韦与体重：我们最终是否打破了平衡？ John R Koethe Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e275–e277, https://doi.org/10.1093/cid/ciaf566 39 Long-Term Clinical, Immunologic, and Viral Reservoir Outcomes in Children Treated With VRC01LS and 10-1074 Monoclonal Antibodies in the Tatelo Study 在Tatelo研究中，接受VRC01LS和10-1074单克隆抗体治疗的儿童的长期临床、免疫学和病毒储存库结局 Gbolahan Ajibola and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e278–e285, https://doi.org/10.1093/cid/ciaf568 40 Trends in Persons Prescribed HIV Postexposure Prophylaxis in the United States, 2015–2023 2015-2023年美国开具HIV暴露后预防处方的患者趋势 John N Le and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e286–e295, https://doi.org/10.1093/cid/ciaf581 Immunocompromised Hosts（免疫功能低下宿主） 41 Epidemiology, Risk Factors, and Outcomes of Neutropenic Enterocolitis in Onco-Hematological Patients According to Chemotherapy Regimen 根据化疗方案分析肿瘤血液学患者中性粒细胞减少性肠结肠炎的流行病学、危险因素和预后 Anne-Sophie Brunel and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e296–e307, https://doi.org/10.1093/cid/ciaf134 42 An Analysis of Cytomegalovirus-Specific Cell-Mediated Immunity in a Phase 3, Randomized, Placebo-Controlled Trial of Letermovir Prophylaxis in Cytomegalovirus-Seropositive Recipients of an Allogeneic Hematopoietic Cell Transplant 在一项3期随机、安慰剂对照试验中，分析来特莫韦预防对巨细胞病毒血清阳性异基因造血细胞移植受者巨细胞病毒特异性细胞介导免疫的影响 Genovefa A Papanicolaou and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e308–e315, https://doi.org/10.1093/cid/ciaf646 43 Cytomegalovirus (CMV)-Specific Cell-Mediated Immunity for Prediction of Postprophylaxis CMV Disease in a Phase 3 Trial of Letermovir Versus Valganciclovir Prophylaxis in Donor CMV-Seropositive/Recipient CMV-Seronegative Kidney Transplant Recipients 在供体巨细胞病毒血清阳性/受体巨细胞病毒血清阴性的肾移植受者中，来特莫韦与缬更昔洛韦预防的3期试验中，巨细胞病毒（CMV）特异性细胞介导免疫对预防后CMV疾病的预测作用 Ajit P Limaye and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e316–e324, https://doi.org/10.1093/cid/ciaf632 44 The Role of Cytomegalovirus-Specific Cellular Immunity in Transplant Recipients with Letermovir Prophylaxis: To be Determined 来特莫韦预防移植受者中巨细胞病毒特异性细胞免疫的作用：有待确定 Yoichiro Natori and Martina Sester Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e325–e327, https://doi.org/10.1093/cid/ciaf633 45 IL12RB1 Deficiency Appearing in North America: Expanding the Clinical Phenotypes 北美出现的IL12RB1缺陷：拓展临床表型 Chen Wang and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e328–e331, https://doi.org/10.1093/cid/ciaf637 Vaccines（疫苗） 46 A Phase IV, Open-label, Single-Arm, Multicentric Clinical Trial for Evaluation of Human Papillomavirus 9vHPV Vaccine Immunogenicity in Men Who Have Sex With Men With HIV: GeSIDA Study 10 017 一项评估人乳头瘤病毒9vHPV疫苗在感染HIV的男男性行为者中免疫原性的IV期、开放标签、单臂、多中心临床试验：GeSIDA 10 017研究 Raquel Ron and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e332–e342, https://doi.org/10.1093/cid/ciaf435 47 Immunogenicity and Safety of the COVID-19 Messenger RNA Vaccine Coadministered With Influenza and 23-valent Pneumococcal Polysaccharide Vaccines 与流感疫苗和23价肺炎球菌多糖疫苗同时接种的COVID-19信使核糖核酸疫苗的免疫原性和安全性 Omid Rezahosseini and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e343–e351, https://doi.org/10.1093/cid/ciaf455 48 Intestinal Mucosal Immune Responses to Novel Oral Poliovirus Vaccine Type 2 in Healthy Newborns 健康新生儿对新型2型口服脊髓灰质炎疫苗的肠道黏膜免疫反应 Audrey Godin and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e352–e360, https://doi.org/10.1093/cid/ciaf484 49 Estimated Vaccine Effectiveness for Respiratory Syncytial Virus–Related Acute Respiratory Illness in Older Adults: Findings From the First Postlicensure Season 老年人呼吸道合胞病毒相关急性呼吸道疾病的估计疫苗有效性：首个上市后季节的研究结果 Sara Y Tartof and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e361–e370, https://doi.org/10.1093/cid/ciaf496 Sexually Transmitted Infections（性传播感染） 50 Systematic Review and Meta-analysis of the Association Between Mycoplasma genitalium and Pelvic Inflammatory Disease (PID) 生殖支原体与盆腔炎性疾病（PID）关联的系统综述和荟萃分析 Kay Htaik and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e371–e379, https://doi.org/10.1093/cid/ciae295 51 Sexually Transmitted Infection (STI)/HIV Testing, STIs, and HIV Pre-exposure Prophylaxis Use Among Men Who Have Sex With Men and Men Who Have Sex With Men and Women in the United States, 2019–2022 2019-2022年美国男男性行为者以及男男性行为者和女性性行为者中性传播感染（STI）/HIV检测、性传播感染和HIV暴露前预防用药情况 Guoyu Tao and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e380–e386, https://doi.org/10.1093/cid/ciae314 52 Cabotegravir Maintains Protective Efficacy in the Setting of Bacterial Sexually Transmitted Infections: A Secondary Analysis of HPTN 083 卡博特韦在细菌性性传播感染情况下维持保护效力：HPTN 083的二次分析 Meredith E Clement and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e387–e395, https://doi.org/10.1093/cid/ciae572 Viral Infections（病毒性感染） 53 Comprehensive Analysis of Cardiovascular Events and Risk Factors in Patients Hospitalized With Respiratory Syncytial Virus 对因呼吸道合胞病毒感染住院患者的心血管事件和危险因素的综合分析 Paulina Sudnik and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e396–e403, https://doi.org/10.1093/cid/ciaf310 54 In Critical Condition: The Urgent Need to Support Mpox Therapeutic and Diagnostic Pipelines 处于危急状况：迫切需要支持猴痘治疗和诊断管线 Carmen Perez Casas and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e404–e408, https://doi.org/10.1093/cid/ciaf529 Correspondence（读者来信） 55 Caution in Interpreting INSTIs and Weight in Observational Studies 在观察性研究中解读整合酶抑制剂与体重关系时需谨慎 Esteban Martínez Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Page e409, https://doi.org/10.1093/cid/ciaf569 56 Weight Trajectories With Integrase Inhibitors: Unaddressed Insights and Limitations in a Chinese Cohort 整合酶抑制剂与体重变化轨迹：中国队列中未解决的见解和局限性 Yuan-Ti Lee and Shiuan-Chih Chen Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e409–e410, https://doi.org/10.1093/cid/ciaf570 57 Real-World Evidence as a Complement to Randomized Trials in Interpreting Weight Gain on Modern INSTI Regimens 现实证据作为随机试验的补充，用于解读现代整合酶抑制剂方案导致的体重增加 Xinsheng Wu and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e410–e411, https://doi.org/10.1093/cid/ciaf571 58 C-reactive Protein in TB Meningitis: Signal, Surrogate, or Saboteur? 结核性脑膜炎中的C反应蛋白：信号、替代指标还是破坏因素？ Patrick K Moonan and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e411–e412, https://doi.org/10.1093/cid/ciaf575 59 C-Reactive Protein in Tuberculous Meningitis: A Viable Biomarker for Individualized Care 结核性脑膜炎中的C反应蛋白：个体化护理的可行生物标志物 Lillian Tugume and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e412–e413, https://doi.org/10.1093/cid/ciaf576 60 The Win Ratio Should Be Complemented by Other Win Statistics to Provide a Comprehensive Picture of Relative and Absolute Treatment Effects: The Case Study of the REPRIEVE Trial 胜利比率应与其他胜利统计数据相结合，以全面呈现相对和绝对治疗效果：REPRIEVE试验案例研究 Melissa J Hardy and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e413–e414, https://doi.org/10.1093/cid/ciaf587 61 Small Effects, Big Impact: Multiple Win Measures Aid Interpretation, But Do Not Forget the Bigger Picture 效应虽小，影响重大：多种胜利衡量指标有助于解读，但不要忘记整体情况 Emma Davies Smith and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e414–e416, https://doi.org/10.1093/cid/ciaf588 62 Does Oral Antibiotic Switching Therapy Show Similar Efficacy to Intravenous Administration for Treating Infective Endocarditis? 口服抗生素转换疗法治疗感染性心内膜炎的疗效是否与静脉给药相似？ Jun Suzuki and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e416–e417, https://doi.org/10.1093/cid/ciaf598 63 Toward a Wider Use of Oral Antibiotic Switch in Infective Endocarditis 朝着更广泛地使用感染性心内膜炎口服抗生素转换疗法迈进 Romane Pouy and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e417–e418, https://doi.org/10.1093/cid/ciaf599 64 Operationalizing Sepsis Definitions With Artificial Intelligence: Toward Smarter Antibiotic Use 利用人工智能实现败血症定义的落地应用：迈向更明智的抗生素使用 James S Ford and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e418–e419, https://doi.org/10.1093/cid/ciaf601 65 Balancing Innovation in Artificial Intelligence With Practical Sepsis Definitions 平衡人工智能创新与实用的败血症定义 Chanu Rhee and Michael Klompas Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e419–e420, https://doi.org/10.1093/cid/ciaf602 66 Precision Prevention of Tuberculosis in Biologic Therapy: Lessons Beyond Screening Strategies 生物疗法中结核病的精准预防：筛查策略之外的启示 Shiuan-Chih Chen and Yuan-Ti Lee Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e420–e421, https://doi.org/10.1093/cid/ciaf559 67 Recalibrating COVID-19 Booster Policy: Lessons From Hybrid Immunity and Global Equity Gaps 重新调整COVID-19加强针政策：从混合免疫和全球公平差距中吸取教训 Nathkapach K Rattanapitoon and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e421–e422, https://doi.org/10.1093/cid/ciaf605

2026-02-26

·北京医学感染与传染研究

临床传染病学 82卷 2期（2026年2月26日更新）

Clinical Infectious Diseases Volume 82 Issue 2 临床传染病学 82卷 2期 https://academic.oup.com/cid/issue/ ID Art Through the Ages（穿越时代的传染病技艺） 1 Interior of the Old Jersey Prison Ship in the Revolutionary War 美国革命战争中老泽西监狱船的内部景象 Mary Grizzard and Michael Grizzard Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Page i, https://doi.org/10.1093/cid/ciaf693 In the Literature（本期精选） 2 In the Literature 本期精选 Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages ii–v, https://doi.org/10.1093/cid/ciag011 IDSA 2025 Collections Editorial（美国传染病学会2025年专题合集社论） 3 2025 Content Collections from the IDSA Journals IDSA期刊2025年内容合集 Roger Bedimo and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 185–186, https://doi.org/10.1093/cid/ciag041 State-of-the-Art Review（前沿综述） 4 State-of-the-Art Review: Chagas Disease—an Enduring Challenge 前沿综述：恰加斯病——一个持续存在的挑战 Nelson Iván Agudelo Higuita and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 187–205, https://doi.org/10.1093/cid/ciaf654 IDSA Features（美国传染病学会特色内容） 5 Policy Recommendations to Support Equitable Access to Long-Acting Injectables for HIV Prevention and Treatment: A Policy Paper of the Infectious Diseases Society of America and the HIV Medicine Association 支持公平获取用于艾滋病毒预防和治疗的长效注射剂的政策建议：美国传染病学会与艾滋病毒医学协会的政策文件 Julia L Marcus and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 206–211, https://doi.org/10.1093/cid/ciae648 Voices of ID（传染病之声） 6 A “Terminal Infection” “绝症感染” Jennifer Furin Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 212–214, https://doi.org/10.1093/cid/ciaf332 Invited Commentary（特邀评论） 7 A Rapid Test to Differentiate Viral From Bacterial Infections: Searching for the Holy Grail 区分病毒与细菌感染的快速检测：寻找“圣杯” Lao-Tzu Allan-Blitz and Jeffrey D Klausner Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 215–218, https://doi.org/10.1093/cid/ciaf585 Bacterial Infections（细菌感染） 8 Nonoperative Versus Neurosurgical Treatment of Brain Abscess: An Emulated Trial Nested Within a Nationwide, Population-Based Cohort 脑脓肿的非手术治疗与神经外科治疗：一项基于全国人群队列的模拟试验 Emilie Marie Eriksen and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 219–227, https://doi.org/10.1093/cid/ciaf304 9 What Is the Impact of Anti-Enterococcal Empirical Therapy on Survival of Patients With Enterococcal Bloodstream Infections? 抗肠球菌经验性治疗对肠球菌血流感染患者生存率的影响是什么？ Linda Bussini and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 228–237, https://doi.org/10.1093/cid/ciaf323 10 Adjunctive Fosfomycin for the Treatment of Staphylococcus aureus Bacteremia: A Pooled Post Hoc Analysis of Individual Participant Data From 2 Randomized Trials 辅助使用磷霉素治疗金黄色葡萄球菌菌血症：两项随机试验个体参与者数据的汇总事后分析 Francesc Escrihuela-Vidal and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 238–245, https://doi.org/10.1093/cid/ciaf387 HIV/AIDs（人类免疫缺陷病毒/艾滋病） 11 Kinetics of Non-nucleoside Reverse Transcriptase Inhibitor Resistance-associated Mutations in HIV-1 Proviral Cellular Reservoirs in Non-nucleoside Reverse Transcriptase Inhibitor-experienced Persons 在接受过非核苷类逆转录酶抑制剂治疗的HIV-1感染者中，非核苷类逆转录酶抑制剂耐药相关突变在HIV-1前病毒细胞储存库中的动力学 Thomas Drumel and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 246–251, https://doi.org/10.1093/cid/ciaf430 12 Impact of Different Integrase Strand Transfer Inhibitors on Body Mass Index Among People With HIV Who Newly Started Antiretroviral Therapy in Shenzhen, China: A Real-World Data Analysis 中国深圳新开始抗逆转录病毒治疗的HIV感染者使用不同整合酶链转移抑制剂对体重指数的影响：一项现实数据分析 Lukun Zhang and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 252–261, https://doi.org/10.1093/cid/ciaf466 13 Consequences of Stopping Antiretroviral Treatment in a Persistently Seronegative Individual with HIV-1 HIV-1持续血清阴性个体停止抗逆转录病毒治疗的后果 Marc Wirden and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 262–264, https://doi.org/10.1093/cid/ciaf422 14 Approaches to the Management of Virologic Failure on Dolutegravir-Based Antiretroviral Therapy in the 50 Countries With the Highest Adult HIV Prevalence 在成人HIV患病率最高的50个国家中，多替拉韦为基础的抗逆转录病毒治疗出现病毒学失败的治疗方法 Cameron T Nutt and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 265–273, https://doi.org/10.1093/cid/ciaf444 Mycobacterial Infections（结核分枝杆菌感染） 15 Retrospective Cohort Analysis for Identification of Discordant Rifampicin-resistant Xpert MTB/RIF Assay Results in South Kivu, Eastern Democratic Republic of the Congo, a High Burden Tuberculosis Setting 刚果民主共和国东部南基伍这一结核病高负荷地区，识别利福平耐药不一致的Xpert MTB/RIF检测结果的回顾性队列分析 Bertin C Bisimwa and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 274–281, https://doi.org/10.1093/cid/ciaf451 16 Prevention of Tuberculosis in Patients Treated With Biological Therapies: 20 Years' Experience in a Specialized Tuberculosis Clinic in a Low-prevalence Country 生物疗法治疗患者中结核病的预防：某低流行国家一个专科结核病诊所20年的经验 Sandra Pérez-Recio and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 282–290, https://doi.org/10.1093/cid/ciaf491 17 Reducing Household Tuberculosis Transmission: A Pilot Cluster-Randomized Controlled Trial 减少家庭内结核病传播：一项试点整群随机对照试验 Cinthya Ruiz-Tagle and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 291–298, https://doi.org/10.1093/cid/ciaf526 18 (Un)masking Tuberculosis （揭开）结核病的“面具” Joseph N Burzynski and Neil W Schluger Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 299–300, https://doi.org/10.1093/cid/ciaf528 19 Estimating the Accuracy and Additionality of TB-LAM to Diagnose TB in Children Without HIV (AccuLAM) 评估TB-LAM在无HIV儿童中诊断结核病的准确性和额外价值（AccuLAM） Lucía CarratalàCastro and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 301–303, https://doi.org/10.1093/cid/ciaf525 Sexually Transmitted Infections（性传播感染） 20 Potential Impact of Doxycycline Post-exposure Prophylaxis Prescribing Strategies on Incidence of Bacterial Sexually Transmitted Infections 多西环素暴露后预防用药策略对细菌性性传播感染发病率的影响 Michael W Traeger and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 304–311, https://doi.org/10.1093/cid/ciad488 21 Filling in the Gaps: Updates on Doxycycline Prophylaxis for Bacterial Sexually Transmitted Infections 填补空白：多西环素预防细菌性性传播感染的最新进展 Aniruddha Hazra and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 312–320, https://doi.org/10.1093/cid/ciae062 22 Reported Neurologic Manifestations Among Persons With Syphilis by Stage of Infection—12 States, 2019–2022 2019-2022年12个州按感染阶段划分的梅毒患者报告的神经系统表现 Sarah B Wondmeneh and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 321–325, https://doi.org/10.1093/cid/ciaf015 Viral Infections（病毒性感染） 23 Investigating the Role of Cytomegalovirus as a Cause of Stillbirths and Child Deaths in Low- and Middle-Income Countries Through Postmortem Minimally Invasive Tissue Sampling 通过死后微创组织采样，调查巨细胞病毒在低收入和中等收入国家死胎和儿童死亡原因中的作用 Sithembiso Velaphi and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 326–336, https://doi.org/10.1093/cid/ciaf098 Photo Quiz（影像问答） 24 Bursting at the Seams “撑破” Maxwell Olenski and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 337–340, https://doi.org/10.1093/cid/ciaf488 Viral Infections（病毒性感染） 25 Clinical and Epidemiological Investigation of Vaccine-Derived Poliovirus Type 2 Outbreak in Pakistan During 2019–2021 2019-2021年巴基斯坦2型疫苗衍生脊髓灰质炎病毒疫情的临床和流行病学调查 Nayab Mehmood and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 341–351, https://doi.org/10.1093/cid/ciaf151 26 Inactivated Polio Vaccine Must Be an Essential Part of Polio Eradication 灭活脊髓灰质炎疫苗必须是根除脊髓灰质炎的重要组成部分 Konstantin Chumakov and Stanley A Plotkin Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 352–353, https://doi.org/10.1093/cid/ciaf215 Photo Quiz（影像问答） 27 Intracranial Lesion in a Patient With Chronic Myeloid Leukemia 慢性髓性白血病患者颅内病变 Mohammed Shakeel Sillat and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 354–357, https://doi.org/10.1093/cid/ciaf441 Viral Infections（病毒性感染） 28 Respiratory Syncytial Virus Co-Detection With Other Respiratory Viruses Is Not Significantly Associated With Worse Clinical Outcomes Among Children Aged <2 Years: New Vaccine Surveillance Network, 2016–2020 在<2岁的婴幼儿中，呼吸道合胞病毒与其他呼吸道病毒共同检测与临床预后恶化无显著关联：2016-2020年新疫苗监测网络数据 Justin Z Amarin and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 358–365, https://doi.org/10.1093/cid/ciaf194 29 Transfer of Herpes Simplex Virus Type 1 (HSV-1) Specific T Cells in a Pediatric Patient Post-HSCT With Severe, Acyclovir-resistant HSV-1 Infection 一例异基因造血干细胞移植后严重、阿昔洛韦耐药的单纯疱疹病毒1型（HSV-1）感染患儿的HSV-1特异性T细胞的输注 Astrid Wintering and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 366–369, https://doi.org/10.1093/cid/ciaf125 Clinical Trials（临床实验） 30 Interferon-α Nasal Spray Prophylaxis Reduces COVID-19 in Cancer Patients: A Randomized, Double-Blinded, Placebo-Controlled Trial 干扰素-α鼻喷雾剂预防可降低癌症患者新冠病毒感染率：一项随机、双盲、安慰剂对照试验 Michelle K Yong and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e208–e216, https://doi.org/10.1093/cid/ciaf409 31 A Phase 3, Randomized Trial Investigating the Safety, Tolerability, and Immunogenicity of V116, an Adult-Specific Pneumococcal Conjugate Vaccine, in Pneumococcal Vaccine-Naïve Adults 18–64 Years of Age at Increased Risk of Pneumococcal Disease, STRIDE-8 一项3期随机试验，调查V116（一种成人特异性肺炎球菌结合疫苗）在未接种过肺炎球菌疫苗且患肺炎球菌疾病风险增加的18-64岁年龄段成人中的安全性、耐受性和免疫原性，STRIDE-8试验 Paul T Scott and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e217–e226, https://doi.org/10.1093/cid/ciaf604 32 Effect of Direct-from-blood Bacterial Testing on Antibiotics Administration in Adults Presenting With Acute Infection: A Randomized Trial 直接从血液进行细菌检测对急性感染成年患者抗生素给药的影响：一项随机试验 David C Gaston and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e227–e235, https://doi.org/10.1093/cid/ciaf677 33 The Tantalizing Pursuit for a Perfect Diagnostic Test: Balancing Innovation With Stewardship 对完美诊断检测的诱人追求：平衡创新与管理 K C Coffey and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e236–e238, https://doi.org/10.1093/cid/ciaf674 Global Health and Neglected Tropical Diseases（全球健康与被忽视的热带病） 34 Diagnostic Accuracy of Tuberculosis Screening Tests in a Prospective Multinational Cohort: Chest Radiography With Computer-Aided Detection, Xpert Tuberculosis Host Response, and C-Reactive Protein 在一项前瞻性多国队列研究中，结核病筛查试验的诊断准确性：计算机辅助检测的胸部X光片、Xpert结核宿主反应检测和C反应蛋白 Rebecca Crowder and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e239–e247, https://doi.org/10.1093/cid/ciae549 HIV/AIDs（人类免疫缺陷病毒/艾滋病） 35 Risk Assessment in a Global CVD Prevention Cohort of People With HIV by PCE, PREVENT, and SCORE2 通过PCE、PREVENT和SCORE2对全球心血管疾病预防队列中艾滋病毒感染者进行风险评估 Steven K Grinspoon and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e248–e257, https://doi.org/10.1093/cid/ciaf542 36 REPRIEVE Analysis of New Cardiovascular Risk Calculators in HIV: Underpredicting Risk Means Preventing Fewer Heart Attacks HIV新心血管风险计算器的REPRIEVE分析：低估风险意味着预防的心脏病发作更少 Matthew S Durstenfeld Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e258–e261, https://doi.org/10.1093/cid/ciaf543 37 Comparable Inflammatory and Metabolic Outcomes After Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Continuing Dolutegravir/Lamivudine in Virologically Suppressed Adults With HIV (INSTINCT/GESIDA10918 Study) 在病毒学抑制的HIV感染成人中，转换为比克替拉韦/恩曲他滨/丙酚替诺福韦与继续使用多替拉韦/拉米夫定后的炎症和代谢结局相当（INSTINCT/GESIDA10918研究） Sergio Serrano-Villar and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e262–e274, https://doi.org/10.1093/cid/ciaf565 38 Tenofovir Alafenamide and Body Weight: Have We Finally Tipped the Scale? 丙酚替诺福韦与体重：我们最终是否打破了平衡？ John R Koethe Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e275–e277, https://doi.org/10.1093/cid/ciaf566 39 Long-Term Clinical, Immunologic, and Viral Reservoir Outcomes in Children Treated With VRC01LS and 10-1074 Monoclonal Antibodies in the Tatelo Study 在Tatelo研究中，接受VRC01LS和10-1074单克隆抗体治疗的儿童的长期临床、免疫学和病毒储存库结局 Gbolahan Ajibola and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e278–e285, https://doi.org/10.1093/cid/ciaf568 40 Trends in Persons Prescribed HIV Postexposure Prophylaxis in the United States, 2015–2023 2015-2023年美国开具HIV暴露后预防处方的患者趋势 John N Le and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e286–e295, https://doi.org/10.1093/cid/ciaf581 Immunocompromised Hosts（免疫功能低下宿主） 41 Epidemiology, Risk Factors, and Outcomes of Neutropenic Enterocolitis in Onco-Hematological Patients According to Chemotherapy Regimen 根据化疗方案分析肿瘤血液学患者中性粒细胞减少性肠结肠炎的流行病学、危险因素和预后 Anne-Sophie Brunel and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e296–e307, https://doi.org/10.1093/cid/ciaf134 42 An Analysis of Cytomegalovirus-Specific Cell-Mediated Immunity in a Phase 3, Randomized, Placebo-Controlled Trial of Letermovir Prophylaxis in Cytomegalovirus-Seropositive Recipients of an Allogeneic Hematopoietic Cell Transplant 在一项3期随机、安慰剂对照试验中，分析来特莫韦预防对巨细胞病毒血清阳性异基因造血细胞移植受者巨细胞病毒特异性细胞介导免疫的影响 Genovefa A Papanicolaou and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e308–e315, https://doi.org/10.1093/cid/ciaf646 43 Cytomegalovirus (CMV)-Specific Cell-Mediated Immunity for Prediction of Postprophylaxis CMV Disease in a Phase 3 Trial of Letermovir Versus Valganciclovir Prophylaxis in Donor CMV-Seropositive/Recipient CMV-Seronegative Kidney Transplant Recipients 在供体巨细胞病毒血清阳性/受体巨细胞病毒血清阴性的肾移植受者中，来特莫韦与缬更昔洛韦预防的3期试验中，巨细胞病毒（CMV）特异性细胞介导免疫对预防后CMV疾病的预测作用 Ajit P Limaye and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e316–e324, https://doi.org/10.1093/cid/ciaf632 44 The Role of Cytomegalovirus-Specific Cellular Immunity in Transplant Recipients with Letermovir Prophylaxis: To be Determined 来特莫韦预防移植受者中巨细胞病毒特异性细胞免疫的作用：有待确定 Yoichiro Natori and Martina Sester Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e325–e327, https://doi.org/10.1093/cid/ciaf633 45 IL12RB1 Deficiency Appearing in North America: Expanding the Clinical Phenotypes 北美出现的IL12RB1缺陷：拓展临床表型 Chen Wang and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e328–e331, https://doi.org/10.1093/cid/ciaf637 Vaccines（疫苗） 46 A Phase IV, Open-label, Single-Arm, Multicentric Clinical Trial for Evaluation of Human Papillomavirus 9vHPV Vaccine Immunogenicity in Men Who Have Sex With Men With HIV: GeSIDA Study 10 017 一项评估人乳头瘤病毒9vHPV疫苗在感染HIV的男男性行为者中免疫原性的IV期、开放标签、单臂、多中心临床试验：GeSIDA 10 017研究 Raquel Ron and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e332–e342, https://doi.org/10.1093/cid/ciaf435 47 Immunogenicity and Safety of the COVID-19 Messenger RNA Vaccine Coadministered With Influenza and 23-valent Pneumococcal Polysaccharide Vaccines 与流感疫苗和23价肺炎球菌多糖疫苗同时接种的COVID-19信使核糖核酸疫苗的免疫原性和安全性 Omid Rezahosseini and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e343–e351, https://doi.org/10.1093/cid/ciaf455 48 Intestinal Mucosal Immune Responses to Novel Oral Poliovirus Vaccine Type 2 in Healthy Newborns 健康新生儿对新型2型口服脊髓灰质炎疫苗的肠道黏膜免疫反应 Audrey Godin and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e352–e360, https://doi.org/10.1093/cid/ciaf484 49 Estimated Vaccine Effectiveness for Respiratory Syncytial Virus–Related Acute Respiratory Illness in Older Adults: Findings From the First Postlicensure Season 老年人呼吸道合胞病毒相关急性呼吸道疾病的估计疫苗有效性：首个上市后季节的研究结果 Sara Y Tartof and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e361–e370, https://doi.org/10.1093/cid/ciaf496 Sexually Transmitted Infections（性传播感染） 50 Systematic Review and Meta-analysis of the Association Between Mycoplasma genitalium and Pelvic Inflammatory Disease (PID) 生殖支原体与盆腔炎性疾病（PID）关联的系统综述和荟萃分析 Kay Htaik and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e371–e379, https://doi.org/10.1093/cid/ciae295 51 Sexually Transmitted Infection (STI)/HIV Testing, STIs, and HIV Pre-exposure Prophylaxis Use Among Men Who Have Sex With Men and Men Who Have Sex With Men and Women in the United States, 2019–2022 2019-2022年美国男男性行为者以及男男性行为者和女性性行为者中性传播感染（STI）/HIV检测、性传播感染和HIV暴露前预防用药情况 Guoyu Tao and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e380–e386, https://doi.org/10.1093/cid/ciae314 52 Cabotegravir Maintains Protective Efficacy in the Setting of Bacterial Sexually Transmitted Infections: A Secondary Analysis of HPTN 083 卡博特韦在细菌性性传播感染情况下维持保护效力：HPTN 083的二次分析 Meredith E Clement and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e387–e395, https://doi.org/10.1093/cid/ciae572 Viral Infections（病毒性感染） 53 Comprehensive Analysis of Cardiovascular Events and Risk Factors in Patients Hospitalized With Respiratory Syncytial Virus 对因呼吸道合胞病毒感染住院患者的心血管事件和危险因素的综合分析 Paulina Sudnik and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e396–e403, https://doi.org/10.1093/cid/ciaf310 54 In Critical Condition: The Urgent Need to Support Mpox Therapeutic and Diagnostic Pipelines 处于危急状况：迫切需要支持猴痘治疗和诊断管线 Carmen Perez Casas and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e404–e408, https://doi.org/10.1093/cid/ciaf529 Correspondence（读者来信） 55 Caution in Interpreting INSTIs and Weight in Observational Studies 在观察性研究中解读整合酶抑制剂与体重关系时需谨慎 Esteban Martínez Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Page e409, https://doi.org/10.1093/cid/ciaf569 56 Weight Trajectories With Integrase Inhibitors: Unaddressed Insights and Limitations in a Chinese Cohort 整合酶抑制剂与体重变化轨迹：中国队列中未解决的见解和局限性 Yuan-Ti Lee and Shiuan-Chih Chen Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e409–e410, https://doi.org/10.1093/cid/ciaf570 57 Real-World Evidence as a Complement to Randomized Trials in Interpreting Weight Gain on Modern INSTI Regimens 现实证据作为随机试验的补充，用于解读现代整合酶抑制剂方案导致的体重增加 Xinsheng Wu and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e410–e411, https://doi.org/10.1093/cid/ciaf571 58 C-reactive Protein in TB Meningitis: Signal, Surrogate, or Saboteur? 结核性脑膜炎中的C反应蛋白：信号、替代指标还是破坏因素？ Patrick K Moonan and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e411–e412, https://doi.org/10.1093/cid/ciaf575 59 C-Reactive Protein in Tuberculous Meningitis: A Viable Biomarker for Individualized Care 结核性脑膜炎中的C反应蛋白：个体化护理的可行生物标志物 Lillian Tugume and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e412–e413, https://doi.org/10.1093/cid/ciaf576 60 The Win Ratio Should Be Complemented by Other Win Statistics to Provide a Comprehensive Picture of Relative and Absolute Treatment Effects: The Case Study of the REPRIEVE Trial 胜利比率应与其他胜利统计数据相结合，以全面呈现相对和绝对治疗效果：REPRIEVE试验案例研究 Melissa J Hardy and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e413–e414, https://doi.org/10.1093/cid/ciaf587 61 Small Effects, Big Impact: Multiple Win Measures Aid Interpretation, But Do Not Forget the Bigger Picture 效应虽小，影响重大：多种胜利衡量指标有助于解读，但不要忘记整体情况 Emma Davies Smith and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e414–e416, https://doi.org/10.1093/cid/ciaf588 62 Does Oral Antibiotic Switching Therapy Show Similar Efficacy to Intravenous Administration for Treating Infective Endocarditis? 口服抗生素转换疗法治疗感染性心内膜炎的疗效是否与静脉给药相似？ Jun Suzuki and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e416–e417, https://doi.org/10.1093/cid/ciaf598 63 Toward a Wider Use of Oral Antibiotic Switch in Infective Endocarditis 朝着更广泛地使用感染性心内膜炎口服抗生素转换疗法迈进 Romane Pouy and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e417–e418, https://doi.org/10.1093/cid/ciaf599 64 Operationalizing Sepsis Definitions With Artificial Intelligence: Toward Smarter Antibiotic Use 利用人工智能实现败血症定义的落地应用：迈向更明智的抗生素使用 James S Ford and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e418–e419, https://doi.org/10.1093/cid/ciaf601 65 Balancing Innovation in Artificial Intelligence With Practical Sepsis Definitions 平衡人工智能创新与实用的败血症定义 Chanu Rhee and Michael Klompas Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e419–e420, https://doi.org/10.1093/cid/ciaf602 66 Precision Prevention of Tuberculosis in Biologic Therapy: Lessons Beyond Screening Strategies 生物疗法中结核病的精准预防：筛查策略之外的启示 Shiuan-Chih Chen and Yuan-Ti Lee Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e420–e421, https://doi.org/10.1093/cid/ciaf559 67 Recalibrating COVID-19 Booster Policy: Lessons From Hybrid Immunity and Global Equity Gaps 重新调整COVID-19加强针政策：从混合免疫和全球公平差距中吸取教训 Nathkapach K Rattanapitoon and others Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e421–e422, https://doi.org/10.1093/cid/ciaf605

100 项与盐酸乐卡地平相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D01849	盐酸乐卡地平	C08CA13	DB00528

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
高血压	瑞典	Meda AB	1998-03-28

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
原发性高血压	临床3期	意大利	Recordati SpA	2010-06-08

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ASH2025	N/A	伯基特淋巴瘤	231	CARMEN	淵獵膚襯廠鑰膚觸顧範(餘觸鹹簾艱構遞築壓衊) = 構膚衊鑰遞構壓餘觸積繭夢衊網觸繭構鑰憲鹽 (構窪壓鏇願繭醖簾鹽製, 94 ~ 96) 更多	积极	2025-12-06
				GMALL or derivatives (BFM, BURKIMAB)	淵獵膚襯廠鑰膚觸顧範(齋窪壓衊壓襯衊選艱鏇) = 廠鹽窪夢範膚觸獵淵餘憲襯窪蓋觸鹽淵顧範構 (憲願構範膚構衊顧觸醖, 73 ~ 75) 更多
NCT01093807 (Pubmed \| J Hypertens)	临床2期	高血压	1,039	Placebo	鏇製糧製艱遞淵鏇醖糧(積蓋憲糧蓋壓廠夢願簾) = 範簾齋憲醖憲艱遞顧鹽艱膚構襯獵觸獵窪遞糧 (遞衊憲蓋鏇網範鏇憲製 ) 更多	-	2016-01-01
				Lercanidipine 10mg	鏇製糧製艱遞淵鏇醖糧(積蓋憲糧蓋壓廠夢願簾) = 繭築觸齋壓製蓋鏇遞繭艱膚構襯獵觸獵窪遞糧 (遞衊憲蓋鏇網範鏇憲製 ) 更多